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ABSTRACT 
Effective antiretroviral therapy (ART) is essential for viral suppression (VS) in HIV-infected 
patients. However, there is a lack of nationally representative data on types of ART regimens 
used and their impact on VS. This thesis used self-reported interview and abstracted medical 
record from 2009 Medical Monitoring Project (MMP) to study ART regimen type and related 
health outcomes. Results showed that 88.6% of HIV-infected adults in care was prescribed ART, 
and about half took regimens designated as ‘preferred’ according to U.S ART guidelines. Among 
MMP participants prescribed ART, 62.7% achieved durable VS, 77.8% achieved recent VS, 
83.5% were 100% dose-adherent, and 17.1% reported side effects. Multivariate regression 
analyses revealed that although ART was critical for VS, there were minor differences in health 
outcomes among the major ART classes in the U.S. ART guidelines or six most-commonly used 
regimens. This study could be potentially useful for future strategic planning of HIV care. 
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CHAPTER 1 INTRODUCTION 
1.1 HIV/AIDS  
1.1.1 Background on HIV/AIDS 
Since 1981 when the first case of the acquired immunodeficiency syndrome (AIDS) was 
recognized by Centers for Disease Control and Prevention (CDC) in the United States [1], AIDS 
has caused nearly 30 million deaths as of 2009 [2]. AIDS is now the fourth-biggest killer 
globally. Up to 2010, approximately 34 million people were living with human 
immunodeficiency virus infection (HIV)—the cause of AIDS [3, 4]. AIDS is a pandemic—a 
disease that is actively spreading globally [5]. 
Genetic research has suggested that HIV originated in west-central Africa during the early 
twentieth century [6].  The initial stage after the contraction of HIV is called acute HIV, 
following by a period of clinical latency, it develops to chronic HIV. Without treatment, the 
clinical latency can last from about three years to over 20 years [7], with an average of about 
eight years.  HIV will eventually progress to AIDS, defined by either a CD4+ T cell count below 
200 cells/µL or the occurrence of specific diseases [8]. In 2008, CDC has updated the 
classification system for HIV into three stages based on CD4 count and clinical symptoms [9]:  
Stage 1: CD4 count ≥ 500 cells/µL and no AIDS defining conditions 
Stage 2: CD4 count 200 to 500 cells/µL and no AIDS defining conditions 
Stage 3: CD4 count ≤ 200 cells/µL or AIDS defining conditions 
Major transmission pathways of HIV include unprotected sexual intercourse, contaminated 
blood transfusions, and from mother to child through pregnancy, delivery, or breastfeeding [10]. 
Therefore, a key strategy for the prevention of HIV is to promote safe-sex behaviors and needle-
exchange programs.  
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1.1.2 HIV/AIDS in the United States 
1.1.2.1 Persons Living with a Diagnosis of HIV Infection 
At the end of 2009, an estimated 1,148,200 persons aged 13 and older were living with HIV 
infection in the United States, including 207,600 (18.1%) persons whose infections had not been 
diagnosed [11].  The estimated number of persons living with a diagnosis of HIV infection in the 
46 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting was 
803,771. In the 46 states only, this included 781,756 adults and adolescents, and 2,945 children 
aged less than 13 years at the end of the year [11]. 
1.1.2.2 Persons Living with an AIDS Diagnosis 
At the end of 2009, the estimated number of persons living with an AIDS diagnosis in the 
United States and 6 U.S. dependent areas was 487,968. In the 50 states and the District of 
Columbia, this included 476,186 adults and adolescents, and 546 children aged less than 13 years 
at the end of the year [11].  
1.1.2.3 HIV Incidence 
The estimated incidence of HIV has remained stable overall in recent years, at about 50,000 
new HIV infections per year [12]. Within the overall estimates, however, some groups are 
affected more than others. For instance, MSM continue to bear the greatest burden of HIV 
infection [12]. 
1.1.3 Current HIV/AIDS treatments 
Currently, there is no cure or effective vaccine for HIV or AIDS [13]. However, modern 
clinical treatments are available to extend and improve the lives of patients infected with HIV. 
Azidothymidine (AZT), a reverse transcriptase inhibitor, previously known as a potential 
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anticancer agent, was the first antiretroviral drug for treating AIDS approved by the U.S. Food 
and Drug Administration (FDA) in 1987.  HIV is a member of retroviruses that possess complex 
genomes and exhibit cone-shaped capsid core particles [14, 15]. As a characteristic of all 
retroviruses, HIV's genome is encoded by RNA. The virus replication cycle starts with the 
binding to CD4 on the cell surface, and then followed by fusion into the cell membrane [16, 17], 
reverse transcription catalyzed by reverse transcriptase, integration catalyzed by integrase, and 
viral maturation operated by protease [18, 19].  Therefore, four categories of HIV drugs—
targeting at four important stages of viral replication cycle, have been developed. They are 
entry/fusion inhibitors (EFI), reverse transcriptase inhibitors (NTI, including non-nucleoside 
reverse transcriptase inhibitor (NNRTI) and nucleoside analogue reverse transcriptase inhibitor 
(NRTI)), integrase inhibitors (INI), and protease inhibitors (PI). FDA has approved nine NRTIs, 
including zidovudine (AZT), tenofovir (TDF), lamivudine (3TC), emtricitabine (FTC), abacavir 
(ABC), zalcitabine (ddC), didanosine (ddI), stavudine (d4T), apricitabine (ATC), and five 
NNRTIs, including rilpivirine (RPV), etravirine (ETV), delavirdine (DLV), efavirenz (EFV) and 
nevirapine (NVP) [20]. The PIs are saquinavir (SQV), amprenavir (APV, off-market now), 
fosamprenavir (FOS-APV), indinavir (IDV), nelfinavir (NFV), ritonavir (RTV), atazanavir 
(ATV), lopinavir (LPV), darunavir  (DRV) and tipranavir (TPV) [20]. EFI and INI are relatively 
new categories of HIV drugs. There are one fusion inhibitor, enfuvirtide (T-20), one entry 
inhibitor, maraviroc (MVC) and one INI, raltegravir (RAL) available on the market [20]. In 
1996, combination antiretroviral treatment, known as Highly Active Antiretroviral Therapy 
(HAART), was proposed for its high effectiveness against HIV. Many clinical studies had shown 
that HAART substantially reduce the death rate and illness caused by AIDS, including [21-24]. 
HAART are "cocktails" consisting of at least three medications belonging to at least two classes 
4 
 
of antiretroviral agents [25, 26].  Typically two NRTIs form the backbone of the treatment and 
then enhanced with one more NNRTI or one PI or one INI [25].  
Clinical interventions, such as ART, can delay the progression to AIDS and prolong life after 
HIV infection. ART regimens significantly improves current life qualities and decreases the risk 
of opportunistic infections and cancer—two major causes of death from HIV/AIDS, which 
probably are the result of the progressive failure of the immune system [27-30]. For instance, 
there is a 70% reduced risk of acquiring tuberculosis with treatment [25].  In the developing 
world treatment also improves physical and mental health [31]. Moreover, timely treatment 
reduces the risk of transmission, including both sexual partners’ transmission and mother-to-
child transmission [25]. The United States recommends ART treatment for all HIV-infected 
people regardless of CD4 count or symptoms [32].  
The effectiveness of treatment largely depends on adherence [33]. Therefore, accessibility of 
medical care, strength of social supports, as well the quality of treatment regimens (complexity 
and adverse effects), play important roles in controlling HIV [34, 35].  
This thesis takes advantages of Medical Monitoring Program (MMP), a unique surveillance 
program that combined personal interviews and medical records, to study the status of HIV 
treatment and health conditions of HIV patients receiving medical care in the United States. The 
information gathered here are nationally representative; therefore, they can be valuable for 
reviewing the quality of current medical services of HIV/AIDS, strategic prevention planning, 
and care resource allocation.   
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1.2 Data Sources 
1.2.1 Background of MMP 
The data used in this study were obtained from MMP, a unique supplementary surveillance 
project designed to provide representative, population-based data on clinical status, care, 
outcomes, and behaviors of HIV-infected persons receiving care in the United States [36]. It is 
supported by several government agencies and conducted by state and local health departments 
along with the CDC. The MMP was first piloted in 2004 [37]. It is designed to achieve following 
objectives [38, 39]:  
• describe the clinical and virological status of HIV-infected persons in care; 
• describe the prevalence of co-morbidities related to HIV disease; 
• describe HIV care and support services received and the quality of such services determine 
prevalence of ongoing risk behaviors and access to, and use of, prevention services among 
persons living with HIV; 
• identify met and unmet needs for HIV care and prevention services to inform prevention 
and care planning groups, health care providers, and other stakeholder [39]. 
1.2.1.1 Sampling Design of MMP 
MMP uses three stages sampling design to achieve annual representative samples of adults 
receiving out-patient care for HIV infection in the U.S. [36]: 
First Stage: State Level  
All 50 states, the District of Columbia, and Puerto Rico were eligible for inclusion in MMP. 
A sample was selected proportional to size based on existing HIV/AIDS cases within each area. 
A total of 16 states and 1 U.S. territory were selected based on the availability of funds. The 
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selected states included 6 separately funded cities, resulting in 23 participating project areas. The 
project areas selected are estimated to include 73% of the total HIV/AIDS cases in the U.S. [36]. 
Second Stage: Health Care Facility Level  
Outpatient HIV medical care facilities in the sampled project areas are sampled every two 
years based on the number of patients seen at the facilities. The annual sample of facilities 
includes about 25-50 facilities from each project area representing small, medium, and large HIV 
medical care facilities. Facilities are eligible to participate if they prescribe antiretroviral 
medications or order CD4 and/or HIV viral load (VL) tests in the context of treating and 
managing HIV. Healthcare facilities that participate are expected to represent similar healthcare 
facilities that were not selected to participate [36].  
Third Stage: Patient Level  
A sample of about 100 to 800 patients from each project area was selected from participating 
health care facilities in 2009.  Patients must be at least 18 years old, diagnosed with HIV, and 
receiving care during January to April 2009. Patients who are selected are asked to participate in 
an interview and answer questions about their demographics, behavior pattern and HIV 
care. Patients who participate are expected to represent patients like them that were not selected 
to participate [36].  
1.2.1.2 Data Collection 
A total of 23 project areas were involved in data collection activities for the 2009 MMP data 
collection cycle: Chicago, Illinois; Delaware; Florida; Georgia; Houston, Texas; Illinois; Indiana; 
Los Angeles County, California; Michigan; Mississippi; New Jersey; the state of New York; 
New York City, New York; North Carolina; Oregon; Pennsylvania; Philadelphia, Pennsylvania; 
Puerto Rico; San Francisco, California; Texas; Virginia; and Washington. Figure 1.1 shows the 
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selected 16 states and 1 U.S. territory and color-coded weighted percentage of sampled patients 
in 2009 data collection cycle. Selected HIV patients ≥18 years of age and who received medical 
care during January–April 2009 at an MMP participating facility, if agreed to participate, were 
interviewed once during June 2009–April 2010 regarding their behaviors and medical status 
during the 12 months preceding the interview. In addition, these patients’ medical records were 
abstracted for documentation of medical care for the 12 months preceding the interview. 
Moreover, data were extracted from the National HIV Surveillance System for every patient who 
was selected to participate in MMP in order to provide basic descriptive information [39].  
 
Figure 1.1 Weighted percentage of sampled patients receiving medical care in the United 
States—Medical Monitoring Project, 2009  
Personal Interview: The MMP interview is a face-to-face structured interview with two different 
questionnaire s: the Standard Questionnaire and Short Questionnaire. The Standard Interview 
takes about 45 minutes to complete while the Short Questionnaire is an abridged version of the 
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Standard Questionnaire which takes about 20 minutes. Both questionnaires are available in both 
English and Spanish. Generally the Standard Questionnaire was preferred for collecting 
interview data. Under certain circumstances, patients who are too ill, or non-English, non-
Spanish speaking patients who need a translator, were administered the Short version [39].  
The 2009 Standard Questionnaire consists of 10 modules: Preliminary Information; 
Demographics; Access to Health Care; HIV Treatment and Adherence; Sexual Behavior; Drug 
and Alcohol Use; Prevention Activities; Anxiety and Depression; Health Conditions and 
Preventive Therapy; and Gynecological and Reproductive History.  Electronic versions of all 
questionnaires are provided by CDC, including handheld-assisted personal interview (HAPI) 
device or computer-assisted personal interview (CAPI) device. HAPI and CAPI interview 
applications were developed using Questionnaire Development System (QDS) software (NOVA 
Research Company, Bethesda, Maryland). Paper versions of the questionnaires are provided for 
use in the event of HAPI/CAPI break down. Local questions may be added by individual project 
area. These questions are not transmitted to CDC[39]. 
Medical Record Abstraction (MRA): Medical records are abstracted by project area staff trained 
to abstract clinical information from medical charts and enter the abstracted information into an 
electronic application provided by CDC. The electronic medical record abstraction consists of 4 
data collection forms: Medical History Form (MHF); Surveillance Period Visit Form (SPVF); 
Surveillance Period Summary Form (SPSF); and Surveillance Period Inpatient Form (SPIF). The 
information abstracted reflects patient’s clinical condition from the time first diagnosed as HIV 
positive to the time of interview. Information collection will include the diagnosis of 
opportunistic illnesses, provision of preventive therapies, prescription of antiretroviral 
medications, laboratory results, assessment of adverse events due to medications, and health 
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services utilization. If a patient cannot be located for recruitment, the patient’s medical record is 
abstracted without interview, if allowed under local surveillance authority. To collect complete 
information on the entire surveillance period, which is the 12 months prior the interview, project 
staff needs to abstract medical record information from all facilities where a participant has 
received medical care for HIV infection during the surveillance period.  
Minimal Data Set (MDS): Regardless of level of participation, minimum data are collected on all 
sampled patients. The minimum data set contains basic demographic and clinical data abstracted 
from the same source for each project area, which is the Enhanced HIV/AIDS Reporting System 
(eHARS). Minimal Data is important as it is the most complete dataset from MMP sampling. It 
provides basic descriptive information regarding the population of inference and is critical for 
assessing potential non-response bias for the data collected through interview and medical record 
abstraction [39].  
1.2.2 Sources of Error in the MMP 
Non-coverage Error: The non-coverage error in MMP may come from three sources: (1) 
sampled HIV patients are those older than eighteen and received medical care during January–
April 2009 at an MMP participating facility, therefore those younger patients, or those received 
care only during May—December 2009, or those received care from non-selected or refused-
participation facilities, are not covered; (2) HIV-infected adults who received all of their care 
solely from emergency departments or inpatient facilities will be excluded from MMP as these 
facilities are not covered by MMP facility sampling frame; (3) patients in prisons or military 
bases are excluded from the sampling frame. The first group seems to be the major source of 
non-coverage error. However, a study focused on “time to first annual HIV care visit” using 
2003 data has shown that 88% and 95% HIV patients had their first visit within four and six 
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months, respectively, therefore,  an enrollment period of four-six months should sufficiently 
reflect the patient population seen in a one-year period, including those attending care 
infrequently [40]. On the other hand, the sub-population from 2
nd
 and 3
rd
 sources is relatively 
small comparing to the national disease population of HIV-infected persons. 
Sampling Error: Similar to all of other surveys, interview/MRA data in MMP are collected on 
only a small sample size of the entire disease population. This may lead to sampling error. Strict 
adherence to sampling rules at each of three sampling stages may reduce some of the sampling 
error.  
Non-response Error: Non-response error is a common problem in all surveillance studies. This is 
especially critical for MMP because it uses a three-stage sampling strategy; therefore, non-
response error may occur at each stage. There are unit non-response and item non-response. Unit 
non-response can arise at multiple levels of MMP data collection, for instance, when a selected 
facility refuses to participate, or when a selected patient refuses to participate in the interview or 
cannot be located, or when the provider denies MMP staff access to the medical records. Item 
non-response may arise when data are not completely obtained for all questionnaire or medical 
records items. The advantage of MMP is that data from the minimal data set which contains 
information on all sampled persons, both respondents and non-respondents can be used to create 
non-response weights to reduce non-response bias. 
Measurement Error: The quality of MMP interview data can be disturbed by the question order, 
question wording, response-code precision, recall error, length of interview, interviewer 
technique, coding errors, and simple data entry error. The quality of MMP medical record data is 
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relying on the accuracy and completeness of medical records, as well as abstractor’s technique, 
coding errors and data entry errors. 
1.2.3 Design Variables Related to Data Analysis  
Each participant is coded by a 12-digits ID which consists of 4 digits which identifies the 
project area ID, 4 digits which represents the facility ID, and 4 digits for an assigned patient ID. 
The design of 2009 MMP data comprised 18 strata and 228 clusters which can be identified by 
variables: 
nat_strat_owt = strata variable in matched interview-MRA dataset 
nat_clust_owt = cluster variable in matched interview-MRA dataset 
nat_owt = stratum weight variable in matched interview-MRA dataset 
The weights had been calculated to adjust for probability of selection and non-response [41].  
1.3 Purpose of Study  
ART therapy is a key component of clinical care for HIV/AIDS patients. Studies have shown 
that successful ART can significantly reduce the HIV viral load and delay disease progression 
[42-45].  Consistently suppressed HIV viral load is associated with reduced mortality and a 
lower probability of sexual transmission [46, 47]. Therefore, the pattern of ART prescription and 
adherence are of great interest and has been studied using several large databases [48, 49], such 
as HIV Insight™ (APACHE), Target Management Services (TMS) and Clinical Partners (CP). 
Although such databases provide a rich source of information, none of them are nationally 
representative. In this thesis, we use MMP, a supplementary surveillance program designed to 
cover all HIV patients receiving medical care in the U.S., to achieve the following goals: 
(1) To provide a nationally representative profile of HIV treatments of HIV-infected adults 
receiving care;  
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(2) To project a nationally representative picture of clinical and virological status of HIV 
infected adults in care;  
(3) To characterize patterns of antiretroviral use in HIV infected adults receiving care and 
explore variations in clinical outcomes resulting from different regimens and patient 
characteristics. 
Ultimately, this information can be used to evaluate current clinical services and guide policy 
and funding decisions aimed at improving the quality of care for people living with HIV/AIDS 
throughout the United States and globally. 
 
13 
 
CHAPTER 2 METHODS 
2.1 Study Population
 
HIV infected adults with age of ≥18 years old and received care from any MMP-participating 
facilities were utilized in analysis.  Data files for the 2009 data collection cycle were encrypted 
and transmitted to CDC through a secure data network. Analyses were done on site at MMP data 
management office, Clinical Outcomes Team, Division of HIV/AIDS Prevention, CDC.  
2.1.1 Facility and Participant Response Rates 
For 2009 data collection cycle, the median facility participation rate was 77.8%, ranging 
from 45.2% to 100% in 23 project areas. The median patient participation rate was 61.9 % 
among eligible patients, varying from 26.4 % to 70.5 % in all project areas. Data were collected 
at both the facility level and the patient level. Patient level data was collected for interview, 
MRA and MDS. The raw national response rates for the 2009 cycle were calculated for all 
datasets: Facility (76.5%), Interview (55.5%), MRA (66.1%) and MDS (87.8%). The combined 
response rate is calculated by: overall response rate = Project area response rate × Facility 
response rate × Individual response rate. So the combined national response rates for Interview, 
MRA and MDS were 42.4%, 50.5% and 67.2%, respectively [50].  Overall, of a total of 9400 
persons who were eligible for participation in MMP, 4620 participated, in which 4415 
participants completed standard interview and 4217 participants had matched pairs of interview 
and medical record abstraction. Therefore, to facilitate analysis of self-reported and clinical data, 
we used the matched interview-MRA data with 4217 samples, representing 421,186 patients in 
care in the United States. 
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2.2 Study Variables  
As mentioned earlier, MMP collected three kinds of dataset in 2009 data cycle: self-reported 
interview dataset, medical records abstraction, and minimal dataset.  Our study focused on two 
sections: “HIV Treatment and Adherence” from interview and “Clinical status” from medical 
records abstractions. Viral load, drug adherence, and side effects are the outcome variables of 
interest, while ART regimens and general demographic/behavior characteristics are the risk 
factors. 
2.2.1 Characteristics of Participants (Self-reported) 
Characteristics of participants were obtained from MMP interviews and were covered in two 
parts: demographic characteristics and behavioral characteristics. Demographic characteristics 
included gender, race/ethnicity, age at interview, education level, country or territory of birth, 
time since HIV diagnosis, availability of health insurance, types of health insurance coverage, 
poverty level, yearly income and access to care. The behavioral characteristics included alcohol 
use, smoking, drug use, depression and sexual risk behavior. The detailed categories for each 
characteristic were listed in Table 3.1 and were computed based on one or more interview 
questions.  
2.2.2 ART Treatment and Adherence to ART (Self-reported) 
In the interview process, ART treatment status was asked in two time courses: the history of 
ART use (asked by question T1. Have you ever taken any antiretroviral medicines for your 
HIV?), and the current status of ART use (asked by question T5. Are you currently taking any 
antiretroviral medicines for your HIV?), each followed by a list of commercially available 
antiretroviral medications. The mapping of interview variables to commercial available 
medicines is shown in Table 2.2. For those who did not take ART, the reason for why not using 
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ART was asked, while for those who are currently taking ART, the adherences to dose, 
instruction and schedule,  reason for missed doses, trouble with side effect, insurance for ARTs, 
and satisfaction with ARTs were asked.  [Questionnaire available at 
http://www.cdc.gov/hiv/topics/treatment/mmp/data.htm]  
 
Table 2.1 Mapping of interview/MRA variables to commercial available medicines 
Drug category 
Drug  
abbreviation 
Variable name 
in Interview 
Variable name  
in SPVF 
Variable name  
in SPIF 
Combo  
(total 5) 
AZT/3TC 
COMBCUR combivir1_vf combivira1_if 
 combivir2_vf combivira2_if 
 combivir3_vf combivira3_if 
ABC/3TC/AZT 
TRIZCUR trizivir1_vf trizivira1_if 
 trizivir2_vf trizivira2_if 
 trizivir3_vf trizivira3_if 
ABC/3TC 
EPZICUR epzicom1_vf epzicoma1_if 
 epzicom2_vf epzicoma2_if 
 epzicom3_vf epzicoma3_if 
FTC/TDF 
TRUVCUR truvada1_vf truvadaa1_if 
 truvada2_vf truvadaa2_if 
 truvada3_vf truvadaa3_if 
 truvada4_vf truvadaa4_if 
 truvada5_vf truvadaa5_if 
FTC/TDF/EFV 
ATRIPLA atripla1_vf atriplaa1_if 
 atripla2_vf atriplaa2_if 
 atripla3_vf atriplaa3_if 
NRTI 
(Total 8) 
3TC 
LAMICUR lamivudine1_vf lamivudinea1_if 
 lamivudine2_vf lamivudinea2_if 
 lamivudine3_vf lamivudinea3_if 
ddI 
DAECCUR didanosine1_vf didanosinea1_if 
DIDACUR didanosine2_vf didanosinea2_if 
 didanosine3_vf didanosinea3_if 
 didanosine4_vf didanosinea4_if 
FTC 
EMTRCUR emtricitabine1_vf emtricitabinea1_if 
 emtricitabine2_vf emtricitabinea2_if 
 emtricitabine3_vf emtricitabinea3_if 
TDF 
TENOCUR tenofovir1_vf tenofovira1_if 
 tenofovir2_vf tenofovira2_if 
 tenofovir3_vf tenofovira3_if 
ddC 
ZALCCUR zalcitabine1_vf zalcitabinea1_if 
 zalcitabine2_vf zalcitabinea2_if 
 zalcitabine3_vf zalcitabinea3_if 
 zalcitabine4_vf zalcitabinea4_if 
d4T 
STAVCUR stavudine1_vf stavudinea1_if 
 stavudine2_vf stavudinea2_if 
 stavudine3_vf stavudinea3_if 
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Drug category 
Drug  
abbreviation 
Variable name 
in Interview 
Variable name  
in SPVF 
Variable name  
in SPIF 
AZT 
ZIDOCUR zidovudine1_vf zidovudinea1_if 
 zidovudine2_vf zidovudinea2_if 
 zidovudine3_vf zidovudinea3_if 
 zidovudine4_vf zidovudinea4_if 
 zidovudine5_vf zidovudinea5_if 
ABC 
ABACACUR abacavir1_vf abacavira1_if 
 abacavir2_vf abacavira2_if 
 abacavir3_vf abacavira3_if 
NNRTI 
(Total 4) 
DLV 
DELACUR delaviridine1_vf delavirdinea1_if 
 delaviridine2_vf delavirdinea2_if 
 delaviridine3_vf delavirdinea3_if 
NVP 
NEVICUR nevirapine1_vf nevirapinea1_if 
 nevirapine2_vf nevirapinea2_if 
 nevirapine3_vf nevirapinea3_if 
EFV 
EFAVCUR efavirenz1_vf efavirenza1_if 
 efavirenz2_vf efavirenza2_if 
 efavirenz3_vf efavirenza3_if 
ETV 
TMC etravirine081_vf etravirinea081_if 
 etravirine082_vf etravirinea082_if 
 etravirine083_vf etravirinea083_if  
 etravirine084_vf etravirinea084_if 
PI 
(Total 10) 
APV 
AMPRCUR amprenavir1_vf amprenavira1_if 
 amprenavir2_vf amprenavira2_if 
 amprenavir3_vf amprenavira3_if 
SQV 
SACQCUR saquinavir081_vf saquinavira1_if 
SAC2CUR saquinavir082_vf saquinavira2_if 
 saquinavir083_vf saquinavira3_if 
 saquinavir084_vf saquinavira4_if 
 saquinavir085_vf saquinavira5_if 
LPVr 
LOPICUR LPVRTV1_VF LPVRTVA1_IF 
 LPVRTV2_VF LPVRTVA2_IF 
 LPVRTV3_VF LPVRTVA3_IF 
 LPVRTV4_VF LPVRTVA4_IF 
 LPVRTV5_VF LPVRTVA5_IF 
 LPVRTV6_VF LPVRTVA6_IF 
IDV 
INDICUR indinavir1_vf indinavira1_if 
 indinavir2_vf indinavira2_if 
 indinavir3_vf indinavira3_if 
FPV 
FUSACUR fosamprenavir1_vf fosamprenavira1_if 
 fosamprenavir2_vf fosamprenavira2_if 
 fosamprenavir3_vf fosamprenavira3_if 
 fosamprenavir4_vf fosamprenavira4_if 
ATV 
ATAZCUR atazanavir1_vf atazanavira1_if 
 atazanavir2_vf atazanavira2_if 
 atazanavir3_vf atazanavira3_if 
RTV 
RITOCUR ritonavir1_vf ritonavira1_if 
 ritonavir2_vf ritonavira2_if 
 ritonavir3_vf ritonavira3_if 
NFV NELFCUR nelfinavir1_vf nelfinavira1_if 
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Drug category 
Drug  
abbreviation 
Variable name 
in Interview 
Variable name  
in SPVF 
Variable name  
in SPIF 
 nelfinavir2_vf nelfinavira2_if 
 nelfinavir3_vf nelfinavira3_if 
TPV 
TIPRCUR tipranavir1_vf tipranavira1_if 
 tipranavir2_vf tipranavira2_if 
 tipranavir3_vf tipranavira3_if 
DRV 
PREZCUR darunavir081_vf darunavira1_if 
 darunavir082_vf darunavira2_if 
 darunavir083_vf darunavira3_if 
 darunavir084_vf darunavira4_if 
EFI 
(Total 2) 
T20 
ENFUCUR enfuvirtide081_vf enfuvirtidea1_if 
 enfuvirtide082_vf enfuvirtidea2_if 
 enfuvirtide083_vf enfuvirtidea3_if 
 enfuvirtide084_vf enfuvirtidea4_if 
MVC 
MARAVIRO maraviroc1_vf maraviroca1_if 
 maraviroc2_vf maraviroca2_if 
 maraviroc3_vf maraviroca3_if 
 maraviroc4_vf maraviroca4_if 
 maraviroc5_vf maraviroca5_if 
INI 
(Only 1) 
RAL 
RALTEGRA raltegravir1_vf raltegravira1_if 
 raltegravir2_vf raltegravira2_if 
 raltegravir3_vf raltegravira3_if 
 raltegravir4_vf raltegravira4_if 
 raltegravir5_vf raltegravira5_if 
After the status of individual drug was programmed, the participants were further grouped 
into two categories: took ART vs. not took ART. For those who took ART, they were separated 
into five major categories including preferred-regimens, alternative-regimens, maybe-selected-
regimens, not-recommended-regimens, and other-regimens. The details of first four categories 
were abstracted from the clinical guideline by Department of Health & Human Services (DHHS) 
[32], as listed in Table 2.2. Other medications that were not on DHHS recommendation list were 
grouped into other-regimens. 
Table 2.2 Initial antiretroviral regimens for antiretroviral therapy in naïve patients [32] 
Regimen group Name Combination 
Preferred Regimens 
Regimens with optimal and durable 
efficacy, favorable tolerability and 
toxicity profile, and ease of use 
NNRTI-Based Regimen 1-1.EFV/TDF/FTC
*
 (AI) 
PI-Based Regimens  
1-2.ATVr + TDF/FTC
*
 (AI)  
1-3.DRVr + TDF/FTC
*
 (AI) 
INSTI-Based Regimen 1-4.RAL + TDF/FTC
*
 (AI) 
Alternative Regimens 
Regimens that are effective and 
tolerable but have potential 
NNRTI-Based Regimens  
2-1.EFV + ABC/3TC
*
 (BI) 
RPV/TDF/FTC
*
 (BI) 
RPV + ABC/3TC
*
 (BIII) 
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Regimen group Name Combination 
disadvantages when compared with 
preferred regimens.  
PI-Based Regimens  
2-2.ATVr + ABC/3TC
*
 (BI) 
2-3.DRVr + ABC/3TC
*
 (BII) 
2-4.FPVr + ABC/3TC
*
 or TDF/FTC
*
 (BI) 
2-5.LPVr + ABC/3TC
*
 or TDF/FTC
*
 (BI) 
INSTI-Based Regimen 
EVG/COBI/TDF/FTC
*
 (BI)  
2-6.RAL + ABC/3TC
*
 (BIII) 
Regimens that may be selected  
for some patients but are less 
satisfactory than preferred or 
alternative regimens 
NNRTI-Based Regimen 
3-1.EFV + ZDV/3TC
*
 
3-2.NVP + (ABC/3TC
*
 or TDF/FTCa or 
ZDV/3TC
*
) 
RPV + ZDV/3TC
*
 
PI-Based Regimens 
3-3.(ATV or ATVr or DRVr or FPVr or LPVr 
or SQVr) + ZDV/3TC
*
 
3-4.ATV + ABC/3TC
*
 
3-5.SQVr + (ABC/3TC
*
 or TDF/FTC
*
) 
INSTI-Based Regimen 3-6.RAL + ZDV/3TC
*
 
CCR5 Antagonist-Based 
Regimens 
3-7.MVC + (ABC/3TC or TDF/FTC or 
ZDV/3TC
*
) 
ARV drugs or components 
NOT recommending as initial 
therapy 
 
4-1.ABC/3TC/ZDV (co-formulated) as 
triple-NRTI combination regimen (BI) 
4-2.ABC + 3TC + ZDV + TDF as quadruple-
NRTI combination regimen (BI) 
DRV (unboosted)  
4-3.DLV (BIII)  
4-4.ddI + 3TC (or FTC) (BIII) 
4-5.ddI + TDF (BII) 
EVG/COBI/TDF/FTC + other ARV drugs 
T20 (BIII) 
ETR (BIII) 
4-6.FPV (unboosted) (BIII) 
4-7.IDV (unboosted) (BIII) 
4-8.IDVr (BIII) 
4-9.NFV (BI) 
RTV as sole PI (BIII) 
4-10.SQV (unboosted) (BI) 
4-11.d4T + 3TC (BI) 
4-12.TPVr (BI) 
*
 3TC may substitute for FTC or vice versa. r stands for Ritonavir boosted. 
Rating of Recommendations: A = Strong; B = Moderate; C = Optional 
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized 
trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion 
Italicized letters for those combinations which were not covered in MMP.  
2.2.3 MRA variables 
Information regarding AIDS diagnosis, CD4 count, prescription of ART, and HIV viral load 
was abstracted from the patient’s medical records data. The most recent ART prescription were 
computed from multiple clinical visit forms (SPVF, covered in section V. ANTIRETROVIRAL 
THERAPY (ART), question “Is there documentation of prescription of antiretroviral therapy 
19 
 
(ART) during this inpatient stay?”) and inpatient forms (SPIF, covered in section VIII. 
ANTIRETROVIRAL THERAPY (ART), question “Is there documentation of prescription or 
continuation of antiretroviral therapy (ART) during this visit?”). The mapping of SFVF and 
SPIF variables to commercial available medicines is shown in Table 2.1. Patients with ART 
prescription were further categorized in the same manner for self-reported ART use, as 
mentioned previously. The most recent and durable viral load was also calculated from the SPVF 
and SPIF (SFVF section X. LABORATORY TESTING – FREQUENTLY REPEATED TEST and 
SPIV section VII. INPATIENT LABORATORY TEST RESULTS). [MRA forms available at 
http://www.cdc.gov/hiv/topics/treatment/mmp/data.htm]. Virologic suppression was defined as 
an HIV VL documented in the MRA of undetectable or 200 copies/ml or less.  
2.2 Statistical Analysis 
Statistical analyses were conducted using SAS (version 9.3) and SAS-Callable SUDDAN 
(version 11.0.0). Hypothesis testing results with p-values of 0.05 or less were considered to be 
statistically significant.  
The SURVEY procedures in SAS were used to take into accounts survey study design 
variables, such as strata, cluster, and weights. Frequencies and weighted percentages of selected 
characteristics were calculated using PROC SURVEYFREQ. Then the modified Rao-Scott chi-
square test, a design-adjusted Pearson chi-square test which involves differences between 
observed and expected frequencies [51-53], was used to test differences between groups.  
Prevalence ratio was used in this study to evaluate the relationship between risk factors and 
outcomes. MMP is a cross-sectional study. Cross-sectional studies are observational studies 
typically used to assess the prevalence of disease conditions. Prevalence is the proportion of a 
population found to have a condition (such as a disease) at a time point or during a time period. 
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Therefore, PR was used in preference to the odds ratio (OR) in this study because PR is more 
conservative, consistent, and interpretable relative to the OR in cross-sectional design [54, 55]. 
Two-step analyses were performed to access the association between ART regimens and 
health outcomes (most recent viral load, durable viral load, drug adherence, and trouble with side 
effects): first, the crude bivariate associations were studied using Rao-Scott chi-square test; and 
then, multivariate logistic regression model for complex survey data was constructed to compute 
the unadjusted and adjusted prevalence ratios (aPRs).  The multivariate modeling was done using 
PROC SURVEYLOGISTIC, which fit linear logistic regression models for discrete response 
survey data by the method of maximum likelihood. Demographic factors (including gender, race, 
age at interview, education level, country or territory of birth, time since HIV diagnosis, type of 
health insurance, and poverty level), and behavioral factors (including binge drinking, injection 
and non-injection drug use), as well as clinical status (including nadir CD4 count, type of AIDS, 
and type of ART regimens), are potential confounding variables which were tested for inclusion 
in each of the multivariate regression models. Collinearity among the independent variables was 
assessed. Variables with a p-value less than 0.1 at univariate analysis
 
were entered in the initial 
multivariate model. Furthermore, manual backward stepwise model selection was performed, 
with a p-value of 0.05 criterion for retention of variables in the
 
final model. Possible interaction 
terms were examined one-by-one. Models were compared through the Akaike’s information 
criterion (AIC). Final model was transferred to SUDDAN PROC RLOGIST to report crude PRs 
and aPRs and statistical inferences. Model adequacy was evaluated using Hosmer and 
Lemeshow goodness-of-fit test [56]. Variances of the regression parameters and prevalence 
ratios were computed by the Taylor linearization method, assuming a with replacement (WR) 
design [57]. 
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CHAPTER 3 RESULTS 
3.1 Frequencies and Descriptive Statistics 
3.1.1 General Characteristics  
As listed in Table 3.1, of 4,217 participants from the 2009 MMP data cycle, 71% were male, 
27% were female, and 1% was transgender or intersex. The age groups with the greatest 
proportion of participants were two older groups, 40-49 years (39%) and 50 years or older 
(36%). Most participants were non-Hispanic black (41%) or non-Hispanic white (34%). Majority 
of the patients were born in the United States (87%). There were 23%, 23% and 54% of 
participants who were diagnosed with HIV infection within 5 years, 4 to 9 year, or more than 10 
years, respectively. A total of 8% of participants reported to be homeless at some point during 
the past 12 months.  Among 3,441 (81%) of participants who reported having health insurance 
coverage in the past 12 months, 2,443 (69%) used some public insurance/program and 971 
(30%) had only private health insurance. (Participants could select more than one type of health 
insurance.) Minor (28%) amount of participants who had insurance coverage had some loss of 
insurance in the past 12 months before interview. Around half (51%) of the participants had 
more than high school education. A total of 64% of participants had low yearly family income 
(0-$19,999) and approximately half (54%) were under poverty level [58]. Among participants 
that were diagnosed within 5 years, more than 90% of the participants were able to access to care 
within 3 months after HIV diagnosis.  
Only 99 (2%) participants had used injection drugs, while 1,134 (27%) participants had used 
non-injection drugs in the past 12 months before the interview. There were 720 (16%) binge 
drinkers and 1,780 (42%) current smokers among 4,217 participants. Majority (74%) of the 
participants did not report depression. Among 68% participants that were sexually active in the 
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past 12 months before the interview, approximately half (45%) had unprotected anal or vaginal 
intercourse, within which 543 (53%) were reported for unprotected intercourse with a partner of 
negative or unknown HIV status.  
Table 3.1 General characteristics of HIV-infected adults receiving medical care in the United 
States—Medical Monitoring Project, 2009  
Characteristic 
No. in sample 
(un-weighted n) 
Estimated 
population size 
(weighted n) 
Weighted 
% 
95% CI of 
percentage 
Total patients     4217   421186    100.0  
Demographic 
Gender 
 Male     3013   299808     71.2 (68.0-74.4) 
 Female     1139   114527     27.2 (24.0-30.4) 
 Transgender or intersex       65     6852      1.6 (1.1-2.2) 
Age at interview 
 18-29      316    31081      7.4 (6.2-8.6) 
 30-39      722    72150     17.1 (15.3-18.9) 
 40-49     1647   165506     39.3 (37.5-41.1) 
 50+     1532   152450     36.2 (34.3-38.1) 
Race/Ethnicity 
 Non-Hispanic Black     1740   174449     41.4 (33.3-49.6) 
 Hispanic      881    80606     19.1 (14.2-24.1) 
 Non-Hispanic White     1395   145586     34.6 (28.0-41.1) 
 Other      199    20339      4.8 (3.8-5.8) 
Foreign born (Country of birth other than US or Puerto Rico) 
 Born in US or Puerto Rico     3685   365912     86.9 (84.8-89.0) 
 Country of birth other than US or 
Puerto Rico 
     529    55094     13.1 (11.0-15.2) 
Length of time since HIV diagnosis 
 0-4 years      951    97527     23.2 (21.2-25.2) 
 5-9 years      978    96988     23.1 (21.5-24.6) 
 10+ years     2283   226161     53.8 (51.2-56.3) 
Homeless at any time in P12M 
 No     3827   383292     91.0 (89.8-92.2) 
 Yes      390    37894      9.0 (7.8-10.2) 
Insurance 
Type of health insurance during P12M 
 Private only      971   100516     23.9 (19.9-28.0) 
 Any public     2423   234888     55.9 (52.6-59.3) 
 No insurance/coverage      768    79234     18.9 (15.1-22.7) 
 Unknown/unspecified insurance       47     5359      1.3 (0.5-2.0) 
Continuous insurance during P12M 
 Continuous insurance/coverage     3020   300481     71.6 (67.2-76.0) 
 Lapsed insurance/coverage      417    39938      9.5 (8.2-10.8) 
 No insurance/coverage      768    79234     18.9 (15.1-22.7) 
Socioeconomic status 
Education attainment 
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Characteristic 
No. in sample 
(un-weighted n) 
Estimated 
population size 
(weighted n) 
Weighted 
% 
95% CI of 
percentage 
 < High School      985    95077     22.6 (20.0-25.1) 
 High school diploma or GED     1161   113016     26.8 (24.1-29.6) 
 > High School     2070   212981     50.6 (45.8-55.4) 
Yearly income during P12M 
 $0-$19,999     2699   261705     64.4 (59.8-69.0) 
 $20,000-$39,999      690    71737     17.7 (15.4-19.9) 
 ≥ $40,000      691    72939     17.9 (14.8-21.1) 
Poverty Level during P12M 
 Above poverty level     2214   228285     54.2 (50.0-58.4) 
 At or below poverty level     1866   178097     42.3 (38.3-46.3) 
 Unknown      137    14805      3.5 (2.5-4.5) 
Access to care 
Time to enter care since 1st HIV positive test for those diagnosed <=5 years 
 ≤ 3 mos.      846    86812     90.9 (88.8-93.0) 
 4-11 mos.       62     5914      6.2 (4.5-7.9) 
 ≥ 12 mos.       28     2754      2.9 (1.8-4.0) 
Behaviors 
Any non-injection drug use 
 No     3071   306072     72.9 (71.1-74.8) 
 Yes     1134   113565     27.1 (25.2-28.9) 
Any injection drug use 
 No     4108   410926     97.9 (97.1-98.8) 
 Yes       99     8767      2.1 (1.2-2.9) 
Binge drinker 
 No     3464   349234     83.6 (82.2-84.9) 
 Yes      720    68551     16.4 (15.1-17.8) 
Current smoker 
 No     2427   241965     57.6 (54.9-60.3) 
 Yes     1780   177980     42.4 (39.7-45.1) 
Depression 
Depression diagnosis based on an algorithm from [59] 
 No depression     3128   309479     74.4 (72.6-76.2) 
 Other depression      535    54689     13.1 (12.0-14.3) 
 Major depression      506    51750     12.4 (11.2-13.7) 
Sexual behavior 
Sexual activity in P12M 
 No, not sexually active in the P12M     1556   159959     38.2 (35.8-40.5) 
 Sexually active in the P12M     2641   259236     61.8 (59.5-64.2) 
Had unprotected sex among sexually active 
 No     1254   122078     54.7 (50.1-59.2) 
 Yes     1032   101220     45.3 (40.8-49.9) 
Had unprotected sex with partner of negative or unknown status among those who reported 
unprotected sex 
 No      478    47458     47.4 (42.0-52.9) 
 Yes      543    52635     52.6 (47.1-58.0) 
Sexual transmission risk category 
 Any MSM (MSM only+MSMW)     1950 196519       46.7 (42.1-51.4) 
 MSW only     1029    99285 23.6 (21.0-26.3) 
 Any WSM (WSM only+WSMW)     1111 111268    26.5 (23.4-29.6) 
 Other      121 13418     3.2 (2.4-4.0) 
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3.1.2 Characteristics of Clinical Status 
Clinical status data were abstracted from 46,829 care visits (including 46,297 outpatient 
visits and 532 inpatient visits) by 4,217 patients during the one-year surveillance period (SP) of 
2009. Of the 4,217 patients, 2,940 (69.6%) had 3 or more tests for VL or CD4 within the SP. 
There were 2,897 (67.6%), 976 (23.9%) and 333 (8.5%) of participants in each of the 3 stages of 
AIDS according to CDC’s classification guidelines [9]. Majority (89.1%) of participants were 
prescribed ART in the past 12 months before interview. A total of 71.6% participants had a 
suppressed most recent viral load while less, about 57.7% participants had suppressed durable 
viral load. 
Table 3.2 Characteristics of clinical status of HIV-infected adults receiving medical care in the 
United States—Medical Monitoring Project, 2009  
Characteristic 
No. in sample 
(un-weighted 
n) 
Estimated 
population size 
(weighted n) 
Weighted 
% 
95% CI of 
percentage 
Total patients     4217   421186    100.0  
Clinical status (MRA) 
Status of AIDS 
 AIDS (Clinical or immunologic)     2897   284022     67.6 (65.7-69.6) 
 No AIDS (Clinical or immunologic)     1309  135980     32.4 (30.4-34.3) 
Types of AIDS 
 AIDS or nadir CD4 0-199     2897   284022     67.6 (65.7-69.6) 
 No AIDS and nadir CD4 200-500      976   100455     23.9 (21.9-25.9) 
 No AIDS and nadir CD4 >500      333    35525      8.5 (7.2-9.7) 
Prescribed antiretroviral (ART) therapy in P12M 
 No      462    45743     10.9 (9.2-12.6) 
 Yes     3737   373733     89.1 (87.4-90.8) 
Geometric mean CD4 count in P12M 
 0-199      543    50476     12.4 (11.0-13.9) 
 200-349      743    74989     18.5 (17.1-19.8) 
 350-499     1011   100507     24.8 (23.4-26.2) 
 500+     1770   179851     44.3 (42.5-46.1) 
Viral suppression: Most recent viral load 
 Most recent viral load > 200 copies/milliliter      1201    119561     28.4 (25.1-31.6) 
 Most recent viral load undetectable or ≤ 200 
copies/milliliter 
    3016   301626     71.6 (68.4-74.9) 
Durable viral suppression: All viral load 
 All viral load > 200 copies/milliliter 1780   178191 42.3 (39.4-45.2) 
 All viral load undetectable or ≤ 200 
copies/milliliter 
    2437   242995     57.7 (54.8-60.6) 
3+CD4/Viral Load in the past 12 months  
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Characteristic 
No. in sample 
(un-weighted 
n) 
Estimated 
population size 
(weighted n) 
Weighted 
% 
95% CI of 
percentage 
 3 or more CD4/VL tests not documented     1257   127277     30.4 (28.0-32.7) 
 3 or more CD4/VL tests documented     2940   292038     69.6 (67.3-72.0) 
3.1.3 Characteristics of HIV/AIDS Treatments 
Of 4,217 participants in 2009 MMP data collection, 3,931 (93.4%) of the participants had a 
history of taking ART. Among 3,609 participants who reported ever having a CD4 T-
lymphocyte test, 2,996 (83%) reported having three or more CD4 T-lymphocyte tests in the 12 
months before the interview. Among 780 participants who were diagnosed within 5 years, 438 
(56.8%) started antiretroviral medication within 3 months after diagnosis. The main reason for 
not currently taking ART medications was doctor’s advises of delaying treatment. For most of 
participants who were on ART, 3,040 (71.6%), the expenses of antiretroviral medicines were 
partially or entirely covered by public programs, such as Medicaid and Medicare. About 12.7% 
and 4.3% of the ART users paid for ART using by private insurance or out-of-pocket payments. 
High ART adherence is essential to achieve viral suppression. In MMP, the ART adherence 
was measured by dose-adherence (taking a right dose or set of pills of prescribed ARTs), 
instruction-adherence (following special instructions for prescribed ART medication) and 
schedule-adherence (following a specific schedule for ART medication) in the past 3 days before 
interview. The majority, 85.6%, 69.0% and 71.7% of the respondents claimed completely 
adherence to dose, instruction (if it was needed) and schedule in the past 3 days, respectively. 
Only 472 (11.5%) of the ART users admitted taking drug holidays, while the main reasons for 
taking drug holidays were side effects (22.2%) or being tired of taking medications (26.2%). A 
total of 645 (17.3%) participants who were on ART reported trouble with side effects from ART 
for half or more than half of the time in the past 30 days. Eighty seven percent of the respondents 
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fully trust the positive effects of ART. Approximately half (48.2%) of the participants took 
complementary therapies in the past 12 months. 
Table 3.3 Characteristics of ART treatments of HIV-infected adults receiving medical care in the 
United States—Medical Monitoring Project, 2009  
Characteristic 
No. in sample 
(un-weighted 
n) 
Estimated 
population size 
(weighted n) 
Weighted 
% 
95% CI of 
percentage 
Total patients     4217   421186    100.0  
HIV treatment (self-reported) 
Ever took ART medication 
  No      280    27764      6.6 (5.5-7.7) 
  Yes     3931   392762     93.4 (92.3-94.5) 
Currently taking ART medication 
  No      576    55525     13.3 (11.9-14.6) 
  Yes     3617   363195     86.7 (85.4-88.1) 
Time between first time ever took ART and first positive test 
  Diagnosed more than 5 Years     3118   308595     79.4 (77.7-81.1) 
  3 months or less      438    45287     11.7 (10.5-12.8) 
  3 months-12 months      162    16555      4.3 (3.6-4.9) 
  12 months or more      180    18021      4.7 (3.9-5.4) 
Reasons for not currently taking antiretroviral medicines 
 Doctor advised to delay treatment      107    10824     50.0 (40.3-59.6) 
 Due to side effects of medication       34     3429     15.8 (9.8-21.8) 
 Other 75     7408     34.2 (26.3-42.1) 
Type of health insurance paid for ART in P12M 
 Not taking ART medication      416    41603      9.9 (8.7-11.1) 
 Paid by private only      511    53451     12.7 (10.4-15.0) 
 Paid by any public program     3040   300933     71.6 (68.2-75.0) 
 Out of pocket      182    18174      4.3 (2.7-5.9) 
 Unspecified/unknown       45     4699      1.1 (0.8-1.4) 
Trust in ART medication producing a positive effect on health 
 Not at all sure      111    11537      3.1 (2.3-3.9) 
 Somewhat sure      347    34799      9.4 (8.0-10.9) 
 Very sure     1251   123159     33.4 (30.6-36.3) 
 Extremely sure     1982   198965     54.0 (50.9-57.1) 
Taking complementary or alternative therapies in P12M 
 No     2164   218152     51.8 (47.1-56.6) 
 Yes     2050   202592     48.2 (43.4-52.9) 
Drug adherence (self-reported) 
Dose adherence in past 3 days 
 No, person is not 100% adherent      526    52024     14.4 (12.9-15.9) 
 Yes, person is 100% adherent     3080   310025     85.6 (84.1-87.1) 
Instruction adherence in past 3 days 
 No, person is not 100% adherent      781    76030     31.0 (28.6-33.4) 
 Yes, person is 100% adherent     1690   169313     69.0 (66.6-71.4) 
Schedule adherence in past 3 days 
 No, person is not 100% adherent     1067   104322     28.3 (25.9-30.7) 
 Yes, person is 100% adherent     2629   264688     71.7 (69.3-74.1) 
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Characteristic 
No. in sample 
(un-weighted 
n) 
Estimated 
population size 
(weighted n) 
Weighted 
% 
95% CI of 
percentage 
Troubled by side effects from ART medication in past 30 days 
 Never     2338   233989     63.4 (61.2-65.7) 
 Rarely      703    70335     19.1 (16.9-21.2) 
 About half the time      279    27315      7.4 (6.5-8.3) 
 Most of the time      191    19929      5.4 (4.7-6.1) 
 Always      175    16678      4.5 (3.5-5.5) 
Understanding of developing resistant to HIV medications if not following instruction 
 Not at all sure      234    23483      6.4 (5.7-7.2) 
 Somewhat sure      441    45058     12.4 (10.6-14.1) 
 Very sure     1253   122789     33.7 (31.0-36.4) 
 Extremely sure     1722   172755     47.4 (44.2-50.7) 
Drug holiday     
 No     3318   334923     88.5 (86.8-90.2) 
 Yes      472    43510     11.5 (9.8-13.2) 
Main reason for drug holiday 
 Medicine has side effects or makes me 
feel bad 
     115     9556     22.2 (18.9-25.5) 
 Got tired of taking medicines or needed 
a break 
     123    11279     26.2 (21.8-30.6) 
 Was using drugs or alcohol       62     5992     13.9 (9.6-18.2) 
 Was on vacation       16     1564      3.6 (2.0-5.3) 
 Felt good       24     1940      4.5 (1.9-7.1) 
 Other      128    12758     29.6 (22.5-36.7) 
3.2 Detail Categories of ART Regimens 
Detailed categories of self-reported and most recently doctor-prescribed ART regimens are 
shown in Figure 3.1. There is a high crude concordance (95.1%) between self-reported ART 
regimens and prescription. 3,605 (86.2%) participants were prescribed ARTs and were currently 
taking ARTs, while 369 (8.9%) participants were not currently taking ARTs, neither were they 
prescribed. The discordance rate is 4.9%, in which 128 (2.9%) were prescribed ART, but did not 
report taking ART in the interview and 91 (2.0%) reported taking ART, but had no record of 
being prescribed ART in the MRA.  
Table 3.4 presents the detailed individual regimen comparison of self-reported and prescribed 
ART regimens. Of 3,605 participants who were prescribed and reported taking ART, 2,562 
(71.1%) participants reported using the exact same ART regimen as latest prescription. The 
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major discrepancies were between “preferred-regimens” and “other-regimens”. The overall 
concordance at individual regimen level is (2,562 [took=prescribed] + 369 [did not take/not 
prescribed]) /4,217), that is 69.5%. ART prescription records were believed to be more accurate 
than the self-reports because the interview data could be biased due to recall for two reasons: (1) 
major HIV antiretroviral medications, HAART, were involved in multiple drugs—a medication 
“cocktail”, (2) each drug has several different commercial brand name. Therefore, further 
analyses were based on most recently prescribed regimens abstracted from the medical records. 
Of 3,737 participants who were prescribed ART, close to half of (1,841 (43.7%)) were 
prescribed preferred-regimens. The proportions of participants who were prescribed alternative-
regimens, maybe-selected-regimens, not-recommended-regimens and other-regimens were 
14.3%, 10.4%, 6.7% and 13.6%, respectively. Such frequency trend is in good agreement with 
the recommendations for antiretroviral regimen by DHHS guidelines [32]. The further 
compositions of individual regimens and their popularities were presented in Table 3.5. The top 
three ART regimens with frequency over 300 were (1-1) EFV/TDF/FTC, a combination of 
NNRTI and NRTI, prescribed to 1,065 (29.3%) of the participants; (1-2) ATVr with TDF/FTC, a 
combination of NRTI and PI, prescribed to 520 (13.4%) of the participants; and (2-5) LPVr with 
ABC/3TC or TDF/FTC, also a combination of NRTI and PI, prescribed to 325 (8.8%) of the 
participants. The second line of ART regimens with frequency around 150 were (3-2) one 
NNRTI (NVP) and two NRTIs (ABC/3TC or TDF/FTC or ZDV/3TC), prescribed to 154 (4.0%) 
of the participants; (1-3) one PI (DRVr) with two NRTIs (TDF and FTC), prescribed to 150 
(4.0%) of the participants; and (3-3) any one PI (ATV or ATVr or DRVr or FPVr or LPVr or 
SQVr) with two NRTIs (ZDV and 3TC), prescribed to 148 (3.8%) of the participants. 
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Figure 3.1 Self-reported and most recently prescribed ART regimens of HIV-infected adults receiving medical care in the United 
States—Medical Monitoring Project, 2009  
(Note: Data in category of “unknown” were not included in calculation of concordance)
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Table 3.4 Comparison of individual self-reported and prescribed ART regimen of HIV-infected adults in MMP 2009 data 
Self-reported 
current 
regimen 
Prescribed regimen (Gold standard) 
Preferred Alternative regimens Regimens maybe selected Regimens NOT recommended Other regimens Total 
1-1 1-2 1-3 1-4 2-1 2-2 2-3 2-4 2-5 2-6 3-1 3-2 3-3 3-4 3-5 3-6 3-7 4-1 4-3 4-4 4-5 4-6 4-7 4-9 4-10 4-11 4-12 5-1 5-2 5-3 5-4  
Preferred 
regimens 
(1) 
1-1 956 6 3 2 3 1 1 1 10 0 0 1 2 2 0 0 0 0 0 0 2 2 0 0 1 0 0 2 1 2 24* 1022 
1-2 6 371 1 2 0 3 0 1 2 0 0 0 2 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 60* 449 
1-3 1 1 100 6 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 3 1 0 10 125 
1-4 3 1 3 62 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 3 0 1 9 85 
Alter-
native 
regimens 
(2) 
2-1 1 0 1 0 45 0 0 0 1 1 0 0 1 2 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 9 63 
2-2 0 4 1 0 0 51 0 0 1 0 0 0 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 4 69 
2-3 0 0 0 0 0 0 10 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 16 
2-4 2 1 0 0 0 0 0 69 0 0 0 0 0 0 1 0 1 0 0 0 0 7 0 0 0 0 0 1 0 0 1 83 
2-5 4 3 3 6 1 0 1 0 264 0 1 0 1 1 0 0 0 1 1 0 2 0 1 1 1 1 0 0 1 17 7 318 
2-6 0 0 0 0 0 0 1 0 1 12 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 17 
Regimens 
maybe 
selected  
(3) 
3-1 4 0 0 0 0 0 0 0 0 0 59 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 8 74 
3-2 2 3 0 0 0 0 0 2 1 0 0 140 1 0 1 0 0 0 0 0 1 0 0 2 0 0 0 3 0 0 13 169 
3-3 1 6 0 0 0 3 1 1 1 0 0 1 106 2 0 1 1 0 0 2 0 2 0 1 0 0 0 1 0 5 11 146 
3-4 0 1 0 0 0 5 0 0 0 0 0 0 0 28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 39 
3-6 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 9 
3-7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
Regimens 
NOT 
recom-
mended  
(4) 
4-1 1 1 1 0 0 0 0 0 0 0 1 0 3 0 0 0 0 35 0 0 1 0 0 0 0 0 0 0 0 0 2 45 
4-3 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 2 8 
4-4 0 3 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 10 1 0 0 0 0 0 0 0 0 0 7 22 
4-5 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 2 15 0 0 0 0 0 0 0 0 0 3 22 
4-6 4 0 0 0 0 0 0 5 1 0 0 0 0 0 1 0 0 0 0 1 0 36 0 0 2 0 0 1 0 0 2 53 
4-7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 8 0 0 0 0 0 0 0 0 9 
4-9 2 5 0 0 0 1 1 0 1 0 0 1 1 0 0 0 0 2 0 0 1 1 1 62 0 0 0 1 0 5 5 90 
4-11 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 11 0 0 0 0 6 21 
4-12 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 6 0 1 0 0 11 
Other 
regimens 
(5) 
5-1 1 1 5 3 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 37 0 0 8 58 
5-2 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 3 
5-3 2 3 0 1 0 0 0 0 12 0 0 1 1 1 0 0 0 1 0 0 2 0 0 0 4 0 0 1 0 59 6 94 
5-4 26* 67* 18 15 5 8 1 12 8 5 1 5 9 5 6 0 1 1 0 2 6 2 1 3 13 1 0 8 0 2 167 398 
Unspecified 19 17 2 2 2 5 1 4 5 0 4 1 4 2 1 0 0 0 0 1 2 2 0 0 0 0 0 3 0 0 9 86 
Total 1037 497 140 101 57 77 17 97 312 19 66 151 137 49 10 7 4 41 4 18 36 56 11 69 23 14 7 66 4 93 385 3605 
% Concord. 92 75 71 61 79 66 59 71 85 63 89 93 77 57 0 86 25 85 75 56 42 64 73 90 0 79 86 56 0 63 --- 71 
*Major discrepancies between self-reported and prescribed ART are shown in red. Agreement between self-reported and prescribed ART regimen are highlighted in yellow. 
Coding of the regimens: the 1st number represents the major regimen group while the 2nd number stands for the order within that group in ART recommendation list (Table 2.2).
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Table 3.5 Most recently prescribed ART regimens of HIV-infected adults receiving medical care 
in the United States—Medical Monitoring Project, 2009  
Prescribed 
Regimen 
Regimen detail combination Freq. 
Weighted 
n 
Weighted 
% 
95% CI  
Total 3737 373733 100.0   
Preferred 
regimens (1) 
1-1.EFV/TDF/FTC
*
 (AI) 1064 109385 29.3 (26.7-31.8) 
1-2.ATVr + TDF/FTC
*
 (AI)  520 50021 13.4 (11.5-15.3) 
1-3.DRVr + TDF/FTC
*
 (AI) 150 14993 4.0 (3.1-4.9) 
1-4.RAL + TDF/FTC
*
 (AI) 106 10685 2.9 (2.2-3.5) 
Alternative 
regimens (2) 
2-1.EFV + ABC/3TC
*
 (BI) 59 5885 1.6 (1.2-2.0) 
2-2.ATVr + ABC/3TC
*
 (BI) 79 7512 2.0 (1.5-2.5) 
2-3.DRVr + ABC/3TC
*
 (BII) 19
#
 2165
#
   
2-4.FPVr + ABC/3TC
*
 or TDF/FTC
*
 (BI) 100 9471 2.5 (1.9-3.2) 
2-5.LPVr + ABC/3TC
*
 or TDF/FTC
*
 (BI) 325 32762 8.8 (7.7-9.8) 
2-6.RAL + ABC/3TC
*
 (BIII) 19 1781 0.5 (0.3-0.7) 
Regimens 
maybe 
selected (3) 
3-1.EFV + ZDV/3TC
*
 68 6440 1.7 (1.2-2.3) 
3-2.NVP + (ABC/3TC
*
 or TDF/FTCa or ZDV/3TC
*
) 154 15119 4.0 (3.1-5.0) 
3-3.(ATV or ATVr or DRVr or FPVr or LPVr or 
SQVr) + ZDV/3TC
*
 
148 14083 3.8 (2.8-4.8) 
3-4.ATV + ABC/3TC
*
 49 4973 1.3 (0.9-1.8) 
3-5.SQVr + (ABC/3TC
*
 or TDF/FTC
*
) 10
#
 950
#
   
3-6.RAL + ZDV/3TC
*
 7
#
 733
#
   
3-7.MVC + (ABC/3TC or TDF/FTC or ZDV/3TC
*
) 4
#
 491
#
   
Regimens 
NOT re-
commended 
(4) 
4-1.ABC/3TC/ZDV (co-formulated) as triple-NRTI 
combination regimen (BI) 
42 4254 1.1 (0.7-1.5) 
4-3.DLV (BIII)  4
#
 354
#
   
4-4.ddI + 3TC (or FTC) (BIII) 20 2307 0.6 (0.3-1.0) 
4-5.ddI + TDF (BII) 38 3748 1.0 (0.6-1.4) 
4-6.FPV (unboosted) (BIII) 58 5917 1.6 (1.1-2.0) 
4-7.IDV (unboosted) (BIII) 11
#
 1079
#
 0.3 (0.1-0.5) 
4-8.IDVr (BIII)  0       
4-9.NFV (BI) 71 6865 1.8 (1.3-2.3) 
4-10.SQV (unboosted) (BI) 23 2545 0.7 (0.3-1.0) 
4-11.d4T + 3TC (BI) 15
#
 1318
#
   
4-12.TPVr (BI) 7
#
 578
#
     
Other 
regimens (5) 
5-1.Other ART with ETV 69 7136 1.9 (1.4-2.4) 
5-2.Other ART with TPV 4
#
 337
#
   
5-3.LPVr alone 93 9293 2.5 (1.9-3.1) 
5-4.Other ART 401 45743 10.8 (9.3-12.4) 
*
 3TC may substitute for FTC or vice versa. r stands for Ritonavir boosted. 
Rating of Recommendations: A = Strong; B = Moderate; C = Optional 
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized t 
trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion 
#
 Population estimate was not provided because the coefficient of variance exceeded 30%. 
Top 3 popular regimens are highlighted in yellow while second line of popularity in cyan. 
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3.3 Factors Associated with Major ART Regimens Groups 
The demographic pattern of ART prescription in HIV-infected adults receiving care was 
studied using Rao-Scott modified chi-square tests (Table 3.6). Of 3,737 participants who were 
prescribed ART, prescribed major regimen groups were significantly associated with age groups, 
history of diagnosis, poverty level, and the type of insurance patients had. Gender, race, status of 
homeless, education level, and birth country were independent from the major ART regimen 
groups. Further multivariate logistic regression was applied to compare the probability of 
prescribing preferred-regimens over all other four groups (Table 3.7).  After adjustment, 
preferred-regimens were more likely to be prescribed to younger (<50 years old), recently 
diagnosed (< 5 years), and above poverty level patients. Such preference in diagnosis history 
may be explained by the fact that the long-term HIV patients would reserve effective regimens 
from earlier prescription while the regimen categorization system used here was developed 
recently for ART initiation in naïve patients [32]. Compared to those with only private insurance, 
patients with only Ryan White (RW) coverage were more likely to get preferred-regimens, while 
those with only Medicare or both Medicare and Medicaid were less likely to be prescribed 
preferred-regimens. 
Table 3.6 Correlation of major ART regimen groups and demographic characters of patients 
receiving medical care for HIV infection—Medical Monitoring Project, 2009 
Characteristic 
Sample 
size n 
Preferred 
regimens 
(Row%) 
Alternative 
regimens 
(Row%) 
Regimens 
maybe 
selected 
(Row%) 
Regimens 
NOT 
recom-
mended 
(Row%) 
Other 
regimens 
(Row%) 
 
Chi-
square* 
p-value 
Total patients prescribed ART 3737 49.56 15.94 11.45 7.60 15.46  
Gender 0.1945 
Male 2706 50.14 15.80 11.43 6.99 15.65  
Female 971 48.25 16.57 11.85 8.62 14.71  
Transgender or intersex 60 45.13 12.42 5.89 17.59 18.96  
Age at interview <.0001 
18-29 yrs 239 66.27 11.74 8.55 4.65 8.79  
30-39 yrs 615 58.86 15.53 9.40 5.59 10.62  
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Characteristic 
Sample 
size n 
Preferred 
regimens 
(Row%) 
Alternative 
regimens 
(Row%) 
Regimens 
maybe 
selected 
(Row%) 
Regimens 
NOT 
recom-
mended 
(Row%) 
Other 
regimens 
(Row%) 
 
Chi-
square* 
p-value 
40-49 yrs 1476 50.82 15.76 11.29 6.67 15.47  
>=50 yrs 1407 41.48 16.98 12.98 9.93 18.63  
Race/Ethnicity       0.0761 
Non-Hispanic Black 1495 50.64 15.92 11.70 7.33 14.41  
Hispanic 786 51.81 16.10 9.44 9.90 12.75  
Non-Hispanic White 1281 47.83 14.88 12.50 6.78 18.01  
Other 174 44.69 23.71 9.62 5.93 16.05  
Foreign born (Country of birth other than US or Puerto Rico) 0.2884 
No, not born in foreign country  3270 49.00 15.76 11.71 7.88 15.66  
Yes, born in foreign country  465 53.42 17.13 9.71 5.60 14.14  
Length of time since HIV diagnosis <.0001 
<5 years 759 66.52 15.28 8.74 2.61 6.85  
5-9 years 885 52.20 15.47 13.21 7.31 11.81  
>=10 years 2091 42.14 16.40 11.67 9.58 20.21  
Homeless at any time in P12M 0.0806 
No 3402 49.18 15.63 11.72 7.70 15.76  
Yes 335 53.46 19.18 8.59 6.52 12.25  
Type of health insurance during P12M <.0001 
No insurance 497 57.69 17.14 9.62 5.00 10.55  
Only RW 135 68.66 8.86 10.79 4.49 7.20  
Only private 861 54.47 12.84 11.29 7.73 13.66  
Only Medicaid 790 47.29 15.79 11.33 7.78 17.81  
Only Medicare 270 40.17 19.85 12.78 8.20 19.00  
Only Medicare and Medicaid 450 37.06 17.47 16.75 10.12 18.61  
Multiple public 439 47.40 16.94 9.55 5.73 20.38  
Private and public combo 247 47.17 21.64 8.03 10.75 12.42  
Unknown/unspecified insurance 42 53.51 15.30 7.39 7.68 16.12  
Education attainment 0.1749 
  <High School 878 47.82 16.66 11.02 8.67 15.83  
  High School diploma or 
equivalent 
1034 49.58 16.23 12.14 8.87 13.19  
  >High School 1825 50.34 15.46 11.28 6.42 16.51  
Poverty Level during P12M 0.0177 
  Above poverty level 1982 51.49 15.21 11.49 6.36 15.46  
  At or below poverty level 1639 47.15 16.95 11.59 8.94 15.36  
*Rao-Scott modified chi-square test 
Table 3.7 Logistic regression model of factors associated with prescription of preferred-
regimens—Medical Monitoring Project, 2009 
Characteristic Unadjusted PR Adjusted PR 
Gender   
  Male Reference Reference 
  Female 0.96 (0.88, 1.05) 0.95 (0.88, 1.03) 
  Transgender or intersex 0.90 (0.61, 1.32) 0.81 (0.55, 1.20) 
Age at interview     
  18-29 yrs Reference Reference 
  30-39 yrs 0.89 (0.78, 1.01) 0.96 (0.83, 1.11) 
  40-49 yrs 0.77 (0.69, 0.85) 0.90 (0.79, 1.03) 
  >=50 yrs 0.62 (0.54, 0.72) 0.78 (0.67, 0.91) 
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Characteristic Unadjusted PR Adjusted PR 
Race/Ethnicity     
  Hispanic Reference Reference 
  Non-Hispanic Black 0.98 (0.85, 1.12) 1.03 (0.90, 1.18) 
  Non-Hispanic White 0.92 (0.8, 1.07) 0.94 (0.82, 1.07) 
  Other 0.86 (0.68, 1.09) 0.85 (0.69, 1.05) 
Foreign born (Country of birth other than US or Puerto Rico)     
  No, not born in foreign country  1.09 (0.96, 1.24) Not  
  Yes, born in foreign country  Reference significant 
Length of time since HIV diagnosis     
  <5 years Reference Reference 
  5-9 years 1.58 (1.43, 1.74) 1.43 (1.31, 1.57) 
  >=10 years 1.24 (1.13, 1.36) 1.16 (1.07, 1.25) 
Homeless at any time in P12M     
  No 0.92 (0.82, 1.03) Not  
  Yes Reference significant 
Type of health insurance during P12M     
  No insurance 1.06 (0.94, 1.19) 1.04 (0.92, 1.18) 
  Only RW 1.26 (1.10, 1.44) 1.22 (1.04, 1.42) 
  Only private Reference Reference 
  Only Medicaid 0.87 (0.78, 0.97) 0.92 (0.83, 1.02) 
  Only Medicare 0.73 (0.61, 0.87) 0.82 (0.68, 0.98) 
  Only Medicare and Medicaid 0.68 (0.58, 0.79) 0.77 (0.67, 0.89) 
  Multiple public 0.87 (0.72, 1.05) 0.95 (0.80, 1.12) 
  Private and public combo 0.87 (0.72, 1.04) 0.96 (0.83, 1.11) 
  Unknown/unspecified insurance 0.98 (0.72, 1.34) 0.95 (0.72, 1.25) 
Education attainment     
  <High School Reference Not  
  High School diploma or equivalent 1.04 (0.95, 1.13) significant 
  >High School 1.05 (0.97, 1.14)   
Poverty Level during P12M     
  Above poverty level 1.09 (1.01, 1.18) 1.09 (1.00, 1.20) 
  At or below poverty level Reference Reference 
Types of AIDS (Clinical status from MRA)     
  AIDS   Reference Not  
  No AIDS 1.22 (1.12, 1.33) significant 
Nadir CD4 count (cells/mm3)     
  0-199 Reference Not  
  200-349 1.17 (1.07, 1.27) significant 
  350-499 1.13 (0.99, 1.28)   
  500+ 1.10 (0.96, 1.27)   
PR: Prevalence ratio 
PRs that were significantly larger than 1 are colored in red while those significantly less than 1 are in blue. 
3.4 Comparison of ART Regimens 
3.4.1 Comparison of Major Regimen Types 
We selected four outcome variables: durable viral suppression, most recent viral suppression, 
dose-adherence, and side effects, to compare the performance of different ART regimens.  Viral 
suppression was selected because it is the most important indicator of response to ART. Viral 
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load testing serves as a surrogate marker for treatment response and is commonly used in 
evaluating patients’ health condition and clinical progression [32]. On the other hand, high level 
of drug adherence and minimal side effects are two key components in ensuring viral 
suppression with ART.  
Crude associations of major regimen types with outcome variables were assessed in Table 
3.8. Complied with current knowledge, ART was crucial for viral suppression. Among the 
patients not on ART, only 21.5% achieved durable viral suppression and 26.3%  had most-recent 
viral suppression, respectively. These proportions were about 2 times lower than those of 
patients on ART: 66.7% and 79.13% achieved durable and most-recent viral suppression, 
respectively. Moreover, major ART groups were correlated with viral suppression and 
independent from side effects in past 30 days and drug adherences in past 3 days (measured by 
dose-adherence, instruction-adherence, and schedule-adherence). 
One multivariate regression model was built for each for the outcome variable of interest. 
Dose-adherence was used as a surrogate for drug adherence model because (1) it was the most 
complete data among three measurements of adherences, (2) it was highly correlated with the 
other two adherence variables (Rao-Scott modified chi-square p-values of <.0001).  
Logistic regression modeling results indicated that the prevalence ratios of viral suppression 
were similar for those who took preferred-regimens, alternative-regimens, maybe-selected-
regimes and not-recommended regimens. The only difference was for those took other-
regimens—regimens not on DHHS recommended list.  Compared to preferred-regimens, patients 
on other-regimens were less likely to achieve durable viral suppression (prevalence ratio [PR], 
0.86; 95% confidence interval [CI], 0.80-0.93) and most recent viral suppression (PR, 0.88; CI, 
0.84-0.93). Other factors independently associated with durable viral suppression were older age 
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groups (>29 years old); non-Hispanic white, Hispanic and other race/ethnicity; long-term HIV 
patients (diagnosed ≥10 years ago); not homeless; above poverty level; partial or complete 
adherent to medication; without major depression; and with nadir CD4 counts of over 500 (Table 
3.9). Other factors independently associated with most recent viral suppression were non-
Hispanic white and Hispanic race/ethnicity; not homeless; above poverty level; non-binge 
drinker; partial or complete adherent to medication; without any depression; and with nadir CD4 
counts of over 500 (Table 3.9). 
Similar analyses for dose-adherence yielded PRs of 0.95 and 0.94 for maybe-selected-
regimens group and other-regimens group, respectively (CIs of 0.89-1.00 and 0.90-0.98, 
respectively). There were no statistically significant differences in dose adherence for patients on 
preferred-regimens, alternative-regimens, and maybe-selected-regimens. Other factors 
independently associated with 100% dose adherence were older age group (>39 years old), long-
term HIV patients (diagnosed 5-9 years ago), education of high school diploma or equivalent, 
non-binge drinker, those not on non-injection drug, and not depressed (Table 3.10). 
The adjusted prevalence ratio of side effects was 1.34 times as high (CI, 1.04-1.73) for those 
who were on not-recommended-regimens. All other four major regimen groups were equally 
likely for developing side effects. On the other hand, side effects were more likely to be observed 
in participants who was non-Hispanic white and other race/ethnicity, were at or below poverty 
level, not adherent to ART, and suffered other or major depression (Table 3.10). 
3.4.2 Comparison of Top Six Popular Regimens 
As presented in Table 3.5, the top six popular ART regimens were (1-1) EFV/TDF/FTC, (1-
2) ATVr with TDF/FTC, (2-5) LPVr with ABC/3TC or TDF/FTC, (3-2) NVP with (ABC/3TC or 
TDF/FTC or ZDV/3TC), (1-3) DRVr with TDF/FTC, and (3-3) any PIs (ATV or ATVr or DRVr 
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Table 3.8 Crude comparison of major regimens by outcomes of interest—Medical Monitoring Project, 2009 
Most recently prescribed regimen 
Most recent VL 
suppressed 
Durable VL 
suppressed 
100% Adherence Had side effect 
in past 30 days Dose Instruction Schedule 
n=3737 n=2904 n=2345 n=2994 n=1642 n=2553 n=617 
 n Col% n Row% n Row% n Row% n Row% n Row% n Row% 
Preferred-regimens 1840 43.9 1455 79.4 1134 62.3 1512 85.6 842 69.4 1294 73.7 288 16.2 
Alternative-regimens 601 14.1 457 77.8 381 64.2 464 81.0 261 71.0 402 70.5 103 17.2 
Maybe-selected-regimens 440 10.2 353 78.4 307 68.0 356 83.7 160 67.3 287 68.5 61 14.8 
NOT-recommended-regimens 289 6.9 233 80.1 205 69.5 224 81.1 125 67.6 189 70.5 59 20.2 
Other-regimens 567 13.6 406 71.3 318 55.0 438 80.1 254 67.0 381 69.5 106 20.0 
p-value* (5 levels)  0.006 0.0002 0.05 0.74 0.22 0.23 
Did NOT prescribe ART 462 10.9 112 26.3 92 21.5     
*Rao-Scott modified chi-square test 
Table 3.9 Logistic regression models of factors associated with viral suppression in patients receiving ART prescription 
—Medical Monitoring Project, 2009 
Characteristic 
Durable viral suppression Most recent viral suppression 
Sample size 
n (% Durable 
VL 
suppressed) 
Chi-
square*  
p-value 
Unadjusted PR Adjusted PR Sample size 
n (% 
Recent VL 
suppressed) 
Chi-
square*  
p-value 
Unadjusted PR Adjusted PR 
Total patients 3737 (62.7)    3737 (77.8)    
Demographic (Self-reported)         
Gender   <.0001    0.002   
  Male 2706 (64.8)  Reference Reference 2706 (79.8)  Reference Reference 
  Female  971 (57.7)  0.89 (0.84, 0.95) 1.00 (0.95, 1.05)  971 (73.0)  0.92 (0.87, 0.96) 1.00 (0.96, 1.04) 
  Transgender or intersex 60 (49.8)  0.77 (0.60, 0.98) 0.90 (0.74, 1.09) 60 (70.8)  0.89 (0.73, 1.09) 0.98 (0.83, 1.15) 
Age at interview      <.0001    <.0001   
  18-29 yrs  239 (39.3)  Reference Reference  239 (72.0)  Reference Reference 
  30-39 yrs  615 (51.8)  1.32 (1.13, 1.54) 1.23 (1.04, 1.45)  615 (68.8)  0.96 (0.86, 1.06) 0.92 (0.84, 1.01) 
  40-49 yrs 1476 (63.6)  1.62 (1.37, 1.91) 1.39 (1.16, 1.65) 1476 (77.3)  1.07 (0.97, 1.18) 1.00 (0.92, 1.10) 
  >=50 yrs 1407 (70.2)  1.79 (1.55, 2.06) 1.51 (1.27, 1.80) 1407 (83.3)  1.16 (1.06, 1.26) 1.07 (0.99, 1.16) 
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Characteristic 
Durable viral suppression Most recent viral suppression 
Sample size 
n (% Durable 
VL 
suppressed) 
Chi-
square*  
p-value 
Unadjusted PR Adjusted PR Sample size 
n (% 
Recent VL 
suppressed) 
Chi-
square*  
p-value 
Unadjusted PR Adjusted PR 
Race/Ethnicity  <.0001    <.0001   
  Hispanic  786 (64.4)  Reference Reference  786 (79.8)  Reference Reference 
  Non-Hispanic Black 1495 (54.9)  0.85 (0.78, 0.93) 0.86 (0.80, 0.92) 1495 (71.4)  0.89 (0.84, 0.96) 0.91 (0.86, 0.97) 
  Non-Hispanic White 1281 (70.6)  1.10 (1.02, 1.18) 1.03 (0.96, 1.10) 1281 (84.1)  1.05 (1.00, 1.11) 1.01 (0.96, 1.07) 
  Other  174 (61.1)  0.95 (0.84, 1.07) 0.95 (0.85, 1.07)  174 (76.5)  0.96 (0.88, 1.04) 0.96 (0.88, 1.05) 
Foreign born (Country of birth other 
than US or Puerto Rico) 
 
0.04   
 
0.05   
  No, not born in foreign country  3270 (61.9)  Reference Not 3270 (77.3)  Reference Not 
  Yes, born in foreign country   465 (67.7)  1.09 (1.01, 1.19) significant  465 (81.7)  1.06 (1.00, 1.12) significant 
Length of time since HIV diagnosis  0.0004    0.94   
  <5 years  759 (54.0)  Reference Reference  759 (78.3)  Reference  
  5-9 years  885 (66.4)  0.84 (0.75, 0.94) 0.94 (0.84, 1.05)  885 (78.1)  1.01 (0.96, 1.06) Not 
  >=10 years 2091 (64.4)  1.03 (0.96, 1.11) 1.09 (1.02, 1.16) 2091 (77.6)  1.01 (0.95, 1.06) significant 
Homeless at any time in P12M  <.0001    <.0001   
  No 3402 (64.6)  1.50 (1.29, 1.75) 1.26 (1.11, 1.43) 3402 (79.3)  1.26 (1.13, 1.42) 1.11 (1.02, 1.20) 
  Yes  335 (43.0)  Reference Reference  335 (62.7)  Reference Reference 
Education attainment  <.0001    <.0001   
  <High School  878 (56.3)  Reference   878 (70.9)  Reference  
  High School diploma or equivalent 1034 (60.6)  1.08 (0.98, 1.19) Not 1034 (75.0)  1.06 (0.98, 1.14) Not 
  >High School 1825 (66.7)  1.19 (1.10, 1.28) significant 1825 (82.5)  1.16 (1.09, 1.24) significant 
Poverty level during P12M  <.0001    <.0001   
  Above poverty level 1982 (68.6)  1.24 (1.17, 1.32) 1.10 (1.04, 1.16) 1982 (83.2)  1.18 (1.13, 1.22) 1.08 (1.04, 1.12) 
  At or below poverty level 1639 (55.1)  Reference Reference 1639 (70.8)  Reference Reference 
Behavior (Self-reported)         
Injection drug use during P12M            0.37              0.19   
  No    3648 (62.8)  1.12 (1.04, 1.21) Not 3648 (78.0)  1.12 (0.96, 1.32) Not 
  Yes        79 (57.4)  Reference considered      79 (74.6)  Reference considered 
Non-injection drug use during P12M            0.003              0.07   
  No    2745 (64.4)  1.09 (0.91, 1.32) Not  2745 (78.9)  1.06 (1.00, 1.12) Not 
  Yes      980 (57.5)  Reference significant   980 (74.6)  Reference significant 
Binge drinking in P12M            0.01              0.0003   
  No    3083 (63.7)  1.11 (1.02, 1.22) Not  3083 (79.0)  1.11 (1.05, 1.17) 1.04 (1.00, 1.09) 
  Yes      626 (57.2)  Reference significant    626 (71.4)  Reference Reference 
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Characteristic 
Durable viral suppression Most recent viral suppression 
Sample size 
n (% Durable 
VL 
suppressed) 
Chi-
square*  
p-value 
Unadjusted PR Adjusted PR Sample size 
n (% 
Recent VL 
suppressed) 
Chi-
square*  
p-value 
Unadjusted PR Adjusted PR 
Depression in P12M            <.0001              <.0001   
  No depression    2794 (65.8)  Reference Reference  2794 (80.6)  Reference Reference 
  Other depression      475 (56.4)  0.86 (0.77, 0.95) 0.93 (0.85, 1.02)    475 (71.2)  0.88 (0.83, 0.94) 0.94 (0.89, 0.99) 
  Major depression      426 (49.6)  0.75 (0.66, 0.86) 0.84 (0.74, 0.94)    426 (67.8)  0.84 (0.77, 0.92) 0.91 (0.83, 0.99) 
Overall adherence  <.0001    <.0001   
  Not adherent 374 (48.5)  Reference Reference 374 (62.4)  Reference Reference 
  Partial adherent 1193 (61.5)  1.27 (1.06, 1.52) 1.17 (1.02, 1.34) 1193 (78.2)  1.25 (1.12, 1.41) 1.18 (1.08, 1.30) 
  100% adherent 2046 (68.8)  1.42 (1.19, 1.70) 1.27 (1.10, 1.47) 2046 (83.9)  1.35 (1.20, 1.50) 1.25 (1.14, 1.38) 
Clinical status and care (from MRA)         
Type of AIDS  0.02    <.0001   
  No AIDS 1002 (66.8)  1.09 (1.01, 1.18) 1.03 (0.94, 1.12) 1002 (82.9)  1.09 (1.05, 1.14) 1.03 (0.98, 1.09) 
  AIDS  2730 (61.2)  Reference Reference 2730 (76.0)  Reference Reference 
Nadir CD4 count (cells/mm3)  <.0001    <.0001   
  0-199 1928 (59.4)  Reference Reference 1928 (74.6)  Reference Reference 
  200-349 1008 (60.7)  1.02 (0.95, 1.10) 1.00 (0.92, 1.09) 1008 (79.1)  1.06 (1.01, 1.11) 1.01 (0.95, 1.07) 
  350-499  434 (67.1)  1.13 (1.04, 1.23) 1.08 (0.98, 1.19)  434 (81.2)  1.09 (1.02, 1.16) 1.02 (0.95, 1.11) 
  500+  346 (82.1)  1.38 (1.27, 1.51) 1.35 (1.25, 1.46)  346 (89.2)  1.20 (1.12, 1.28) 1.15 (1.07, 1.23) 
Prescribed antiretroviral (ART) 
therapy in P12M 
 
0.0002   
 
0.0055   
  Preferred-regimens 1840 (62.3)  Reference Reference 1840 (79.4)  Reference Reference 
  Alternative-regimens  601 (64.2)  1.03 (0.97, 1.09) 1.00 (0.95, 1.06)  601 (77.8)  0.98 (0.94, 1.02) 0.97 (0.93, 1.01) 
  Maybe-selected-regimens  440 (68.0)  1.09 (1.01, 1.18) 1.03 (0.95, 1.12)  440 (78.4)  0.99 (0.93, 1.05) 0.97 (0.91, 1.03) 
  NOT-recommended-regimens  289 (69.5)  1.12 (1.01, 1.24) 1.05 (0.95, 1.16)  289 (80.1)  1.01 (0.94, 1.08) 0.99 (0.92, 1.06) 
  Other-regimens  567 (55.0)  0.88 (0.80, 0.97) 0.86 (0.80, 0.93)  567 (71.3)  0.90 (0.84, 0.95) 0.88 (0.84, 0.93) 
 PRs that were significantly larger than 1 are colored in red while those significantly less than 1 are in blue. 
*Rao-Scott modified chi-square test 
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Table 3.10 Logistic regression models of factors associated with dose-adherence and side effect in patients receiving ART 
prescription—Medical Monitoring Project, 2009 
Characteristic 
100% Dose adherence Troubled by side effects 
Sample size 
n (% Dose 
adherence 
100%) 
Chi-
square*  
p-value 
Unadjusted PR Adjusted PR Sample size 
n (% Had 
side effect) 
Chi-
square* 
p-value 
Unadjusted PR Adjusted PR 
Total patients 3613 (83.5)    3583 (17.1)    
Demographic (Self-reported)         
Gender   0.01    0.31   
  Male 2636 (84.6)  Reference  2614 (16.4)  Reference  
  Female  921 (80.9)  0.96 (0.93, 0.99) Not  913 (18.9)  1.15 (0.95, 1.38) Not 
  Transgender or intersex 56 (74.8)  0.88 (0.77, 1.02) significant 56 (16.2)  0.99 (0.53, 1.83) significant 
Age at interview      0.02    0.06   
  18-29 yrs  221 (78.2)  Reference Reference  218 (19.4)  Reference Reference 
  30-39 yrs  579 (80.5)  1.03 (0.95, 1.12) 1.06 (0.97, 1.16)  572 (20.1)  1.04 (0.71, 1.52) 1.08 (0.72, 1.61) 
  40-49 yrs 1430 (84.3)  1.08 (1.00, 1.16) 1.13 (1.03, 1.24) 1422 (17.9)  0.93 (0.65, 1.31) 0.92 (0.61, 1.40) 
  >=50 yrs 1383 (84.7)  1.08 (1.01, 1.16) 1.13 (1.04, 1.23) 1371 (14.6)  0.75 (0.55, 1.02) 0.81 (0.56, 1.15) 
Race/Ethnicity  0.02    0.01   
  Hispanic  762 (83.6)  Reference Reference  758 (14.0)  Reference Reference 
  Non-Hispanic Black 1437 (80.5)  0.96 (0.92, 1.01) 0.97 (0.92, 1.01) 1425 (15.5)  1.11 (0.90, 1.36) 1.12 (0.92, 1.37) 
  Non-Hispanic White 1247 (86.9)  1.04 (0.99, 1.10) 1.05 (0.99, 1.11) 1237 (19.9)  1.42 (1.16, 1.74) 1.58 (1.28, 1.94) 
  Other  166 (81.3)  0.97 (0.88, 1.07) 1.01 (0.93, 1.09)  162 (22.3)  1.60 (1.05, 2.43) 1.52 (1.00, 2.32) 
Foreign born (Country of birth other 
than US or Puerto Rico)  
0.91 
 
 
 
0.09 
 
 
  No, not born in foreign country  3157 (83.4)  Reference Not 3131 (17.6)  Reference Not 
  Yes, born in foreign country   454 (83.7)  1.00 (0.95, 1.06) considered  450 (13.6)  0.77 (0.56, 1.06) significant 
Length of time since HIV diagnosis  0.01    0.37   
  <5 years  725 (87.1)  Reference Reference  717 (15.9)  Reference  
  5-9 years  855 (84.1)  1.07 (1.02, 1.11) 1.09 (1.05, 1.14)  849 (15.9)  0.89 (0.73, 1.07) Not 
  >=10 years 2031 (81.8)  1.03 (0.98, 1.08) 1.04 (0.99, 1.10) 2015 (18.0)  0.88 (0.69, 1.13) significant 
Homeless at any time in P12M  0.09    0.06   
  No 3302 (83.9)  1.07 (0.99, 1.16) Not 3278 (16.7)  0.77 (0.61, 0.98) Not 
  Yes  311 (78.5)  Reference significant  305 (21.5)  Reference significant 
Education attainment  0.003    0.02   
  <High School  838 (78.1)  Reference Reference  825 (17.1)  Not Not 
  High School diploma or equivalent  997 (85.5)  1.10 (1.03, 1.16) 1.07 (1.00, 1.13)  992 (14.1)  considered significant 
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Characteristic 
100% Dose adherence Troubled by side effects 
Sample size 
n (% Dose 
adherence 
100%) 
Chi-
square*  
p-value 
Unadjusted PR Adjusted PR Sample size 
n (% Had 
side effect) 
Chi-
square* 
p-value 
Unadjusted PR Adjusted PR 
  >High School 1778 (84.8)  1.09 (1.04, 1.14) 1.04 (0.99, 1.09) 1766 (18.7)    
Poverty level during P12M  0.0002    0.001   
  Above poverty level 1939 (85.8)  1.07 (1.03, 1.10) Not 1927 (15.2)  0.77 (0.66, 0.90) 0.80 (0.69, 0.93) 
  At or below poverty level 1566 (80.5)  Reference significant 1549 (19.6)  Reference Reference 
Behavior (Self-reported)         
Injection drug use during P12M            0.12              0.02   
  No  3533 (83.8)  1.16 (0.98, 1.38) Not 3509 (17.2)  1.59 (0.93, 2.73) Not 
  Yes       70(72.0)  Reference significant 67 (10.8)  Reference significant 
Non-injection drug use during P12M            <.0001    0.48   
  No 2665 (86.5)  1.15 (1.10, 1.20) 1.12 (1.08, 1.17) 2648 (16.8)  0.94 (0.78, 1.12) Not 
  Yes    937 (75.3)  Reference Reference 927 (17.9)  Reference significant 
Binge drinking in P12M            <.0001    0.61   
  No  2986 (85.5)  1.16 (1.10, 1.22) 1.12 (1.07, 1.17) 2965 (17.2)  1.07 (0.83, 1.37) Not 
  Yes    599 (73.8)  Reference Reference 594 (16.1)  Reference significant 
Depression in P12M            0.0006    <.0001   
  No depression  2723 (85.5)  Reference Reference 2711 (12.6)  Reference Reference 
  Other depression   454 (73.8)  0.93 (0.88, 0.99) 0.94 (0.89, 0.99) 445 (23.5)  1.88 (1.54, 2.29) 1.79 (1.47, 2.19) 
  Major depression    396 (76.8)  0.90 (0.84, 0.96) 0.92 (0.86, 0.98) 392 (38.6)  3.08 (2.43, 3.90) 2.89 (2.26, 3.68) 
Overall adherence      <.0001   
  Not adherent     361 (25.0)  Reference Reference 
  Partial adherent     1187(20.6)  0.83 (0.65, 1.05) 0.91 (0.73, 1.14) 
  100% adherent     2034(13.7)  0.55 (0.43, 0.70) 0.66 (0.51, 0.85) 
Clinical status and care (from MRA)         
Type of AIDS  0.21    0.35   
  No AIDS  961 (85.0)  1.03 (0.99, 1.07) Not  952 (16.1)  Not Not 
  AIDs  2647 (82.9)  Reference significant 2626 (17.5)  considered considered 
Nadir CD4 count (cells/mm3)  0.002    0.48   
  0-199 1870 (81.1)  Reference  1856 (17.0)    
  200-349  968 (85.8)  1.06 (1.01, 1.11) Not  958 (18.2)  Not Not 
  350-499  421 (88.2)  1.09 (1.04, 1.14) significant  420 (14.7)  considered considered 
  500+  333 (84.5)  1.04 (0.98, 1.10)   328 (17.4)    
Prescribed antiretroviral (ART) 
therapy in P12M  
0.05   
 
0.22   
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Characteristic 
100% Dose adherence Troubled by side effects 
Sample size 
n (% Dose 
adherence 
100%) 
Chi-
square*  
p-value 
Unadjusted PR Adjusted PR Sample size 
n (% Had 
side effect) 
Chi-
square* 
p-value 
Unadjusted PR Adjusted PR 
  Preferred-regimens 1779 (85.6)  Reference Reference 1762 (16.2)  Reference Reference 
  Alternative-regimens  581 (81.0)  0.95 (0.89, 1.01) 0.96 (0.90, 1.01)  575 (17.2)  1.06 (0.80, 1.42) 1.09 (0.83, 1.42) 
  Maybe-selected-regimens  425 (83.7)  0.98 (0.92, 1.04) 0.97 (0.92, 1.03)  422 (14.8)  0.92 (0.66, 1.28) 1.03 (0.74, 1.42) 
  NOT-recommended-regimens  279 (81.1)  0.95 (0.89, 1.01) 0.95 (0.89, 1.00)  277 (20.2)  1.25 (0.99, 1.58) 1.34 (1.04, 1.73) 
  Other-regimens  549 (80.1)  0.94 (0.89, 0.98) 0.94 (0.90, 0.98)  547 (20.0)  1.24 (0.99, 1.55) 1.21 (0.97, 1.52) 
 PRs that were significantly larger than 1 are colored in red while those significantly less than 1 are in blue. 
*Rao-Scott modified chi-square test 
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or FPVr or LPVr or SQVr) with ZDV/3TC. They were all NRTIs based combinations with 
addition of either NNRTIs or PIs. They were in high ranks on the ART recommendation list as 
well (Table 2.2). Therefore, it will be instructive to compare these six regimens by means of 
associations with viral suppression, and self-reported dose adherence and side effects. 
 Crude associations of top six popular regimens with outcome variables were assessed in 
Table 3.11. There was a statistically significant association between regimens and viral 
suppression (both durable and most recent viral load). Different regimens were also correlated 
with dose adherence and schedule adherence. However, ART regimens were independent from 
instruction adherence and side effects. 
A multivariate logistic regression model was setup for each of the four outcome variables. 
Again, dose-adherence was used as a surrogate for drug adherence. Adjusted prevalence ratios of 
four models were listed in Table 3.12 and Table 3.13. Compared to the most popular regimen—
(1-1) EFV/TDF/FTC, patients on regimens [(1-2) ATVr with TDF/FTC, (2-5) LPVr with 
ABC/3TC or TDF/FTC and (1-3) DRVr with TDF/FTC] were less likely to achieve durable viral 
suppression. The adjusted prevalence ratios were 0.84 (0.76-0.94), 0.88 (0.81-0.96), and 0.69 
(0.56, 0.86) for regimens (1-2), (2-5), and (1-3), respectively. Other two regimens [(3-2) NVP 
with (ABC/3TC or TDF/FTC or ZDV/3TC) and (3-3) any PI (ATV or ATVr or DRVr or FPVr 
or LPVr or SQVr) with ZDV/3TC] were parallel to regimen (1-1).  On the other hand, for most 
recent viral load, patients on regimens (1-2), (2-5), (1-3) and (3-3) were less likely to achieve 
viral suppression. The adjusted prevalence ratios were 0.93 (0.87-1.00), 0.88 (0.82-0.95), 0.88 
(0.79, 0.99) and 0.87 (0.77, 0.99) for regimens (1-2), (2-5), (1-3), and (3-3) respectively. 
Regimens (1-1) and (3-2) had same prevalence on most recent viral suppression. Other factors 
independently associated with durable viral suppression were older age groups (over 30 years 
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old), non-Hispanic white race/ethnicity, birth in foreign country, patients diagnosed more than 10 
years ago, not homeless at any time, 100% adherent to medication, no or other depression, and 
patients with nadir CD4 counts of over 500 (Table 3.12). Other factors independently associated 
with most recent viral suppression were older age group (over 50 years old), diagnosed more 
than 10 years ago, not homeless at any time, partial or 100% drug adherent, and over 500 nadir 
CD4 counts (Table 3.12). 
Similar analyses for dose-adherence yielded PRs of 0.90, 0.91 and 0.90 for regimens (1-2), 
(1-3) and (3-3), respectively (CIs of 0.83-0.97, 0.83-0.99 and 0.84-0.98, respectively). There was 
no statistically significant difference in dose adherence for regimens (1-1), (1-2) and (3-2). Other 
factors independently associated with 100% dose adherence were age group of 40-49, non-binge 
drinker, patients not on non-injection drug, and group without major depression (Table 3.13). 
The prevalence ratio of side effects was 1.65 times as high (CI, 1.16-2.36) for those who 
were regimen (1-3) DRVr with TDF/FTC. All other five regimens did not show statistically 
significant differences in associations with side effects. Besides, side effects were more likely to 
be observed in participants who was non-Hispanic white race/ethnicity, were at or below poverty 
level, and suffered from any depression (Table 3.13). 
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Table 3.11 Crude comparison of top six popular regimens by outcomes of interest—Medical Monitoring Project, 2009 
Most recently prescribed regimen 
Most recent VL 
suppressed 
Durable VL 
suppressed 
100% Adherence Had side 
effect in past 
30 days Dose Instruction Schedule 
n=2357 n=1865 n=1497 n=1917 n=1027 n=1625 n=367 
 n Col% n Row% n Row% n Row% n Row% n Row% n Row% 
1-1.EFV/TDF/FTC
*
 (AI) 1060 46.3 899 84.1 737 69.0 908 87.6 484 70.2 812 78.7 160 15.3 
1-2.ATV/r + TDF/FTC
*
 (AI) 520 21.2 380 74.8 281 55.5 409 83.2 249 68.9 338 69.5 75 14.6 
2-5.LPV/r + ABC/3TC* or TDF/FTC* (BI) 325 13.9 237 73.5 199 61.1 246 78.0 119 65.9 204 64.7 59 18.5 
3-2.NVP + (ABC/3TC
*
 or TDF/FTCa or 
ZDV/3TC
*
) 
154 6.4 140 90.4 123 79.1 131 87.6 38 72.9 112 77.1 23 15.1 
1-3.DRV/r + TDF/FTC
*
 (AI) 150 6.3 103 69.5 65 46.5 112 81.3 74 62.8 79 57.2 33 26.6 
3-3.(ATV or ATV/r or DRV/r or FPV/r or LPV/r 
or SQV/r) + ZDV/3TC
*
 
148 6.0 106 67.6 89 56.9 111 78.7 63 73.1 80 57.4 17 13.8 
p-value
%
  <.0001 <.0001 0.002 0.46 <.0001 0.09 
*
 3TC may substitute for FTC or vice versa.  /r stands for Ritonavir boosted. 
Rating of Recommendations: A = Strong; B = Moderate 
Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational cohort studies with 
long-term clinical outcomes; III = Expert opinion 
%
Rao-Scott modified chi-square test 
Table 3.12 Logistic regression models of factors associated with viral suppression in patients receiving top six popular ART 
regimen—Medical Monitoring Project, 2009 
Characteristic 
Durable viral suppression Most recent viral suppression 
Sample size 
n (% Durable 
VL 
suppressed) 
Chi-
square
%
 
p-value 
Unadjusted PR Adjusted PR Sample size 
n (% Recent 
VL 
suppressed) 
Chi-
square 
p-
value
%
 
Unadjusted PR Adjusted PR 
Total patients 2361 (63.5)    2361 (79.2)    
Demographic (Self-reported)         
Gender   0.02    0.02   
  Male 1719 (65.5)  Reference Reference 1719 (80.8)  Reference Reference 
  Female  610 (58.8)  0.90 (0.82, 0.98) 1.02 (0.95, 1.09)  610 (74.6)  0.92 (0.87, 0.98) 1.02 (0.97, 1.06) 
  Transgender or intersex 33 (49.7)  0.76 (0.51, 1.12) 0.89 (0.67, 1.20) 33 (76.8)  0.95 (0.78, 1.16) 1.02 (0.89, 1.17) 
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Characteristic 
Durable viral suppression Most recent viral suppression 
Sample size 
n (% Durable 
VL 
suppressed) 
Chi-
square
%
 
p-value 
Unadjusted PR Adjusted PR Sample size 
n (% Recent 
VL 
suppressed) 
Chi-
square 
p-
value
%
 
Unadjusted PR Adjusted PR 
Age at interview      <.0001    <.0001   
  18-29 yrs  179 (38.1)  Reference Reference  179 (75.1)  Reference Reference 
  30-39 yrs  432 (54.4)  1.43 (1.18, 1.73) 1.25 (1.02, 1.52)  432 (70.1)  0.93 (0.83, 1.05) 0.91 (0.82, 1.01) 
  40-49 yrs  939 (65.5)  1.72 (1.44, 2.06) 1.40 (1.15, 1.70)  939 (78.9)  1.05 (0.96, 1.15) 1.01 (0.93, 1.09) 
  >=50 yrs  812 (71.6)  1.88 (1.60, 2.21) 1.49 (1.24, 1.79)  812 (85.3)  1.14 (1.04, 1.24) 1.08 (1.00, 1.16) 
Race/Ethnicity  <.0001    <.0001   
  Hispanic  492 (64.2)  Reference Reference  492 (80.6)  Reference Reference 
  Non-Hispanic Black  979 (57.3)  0.89 (0.81, 0.99) 0.93 (0.85, 1.02)  979 (73.9)  0.92 (0.86, 0.98) 0.93 (0.87, 0.99) 
  Non-Hispanic White  784 (71.6)  1.11 (1.01, 1.23) 1.12 (1.02, 1.22)  784 (85.2)  1.06 (1.00, 1.12) 1.02 (0.96, 1.08) 
  Other  107 (55.5)  0.86 (0.73, 1.03) 0.94 (0.82, 1.08)  107 (75.0)  0.93 (0.84, 1.03) 0.97 (0.88, 1.06) 
Foreign born (Country of birth other 
than US or Puerto Rico)  
0.07   
 
0.19   
  No, not born in foreign country  2049 (62.7)  Reference Reference 2049 (78.6)  Reference Not 
  Yes, born in foreign country   313 (69.0)  1.10 (1.00, 1.21) 1.11 (1.02, 1.21)  313 (82.4)  1.05 (0.98, 1.12) significant 
Length of time since HIV diagnosis  <.0001    0.80   
  <5 years  590 (54.3)  Reference Reference  590 (78.9)  Reference Reference 
  5-9 years  587 (67.9)  0.82 (0.74, 0.91) 0.89 (0.80, 1.00)  587 (80.3)  1.00 (0.94, 1.06) 1.02 (0.96, 1.08) 
  >=10 years 1184 (66.3)  1.02 (0.95, 1.10) 1.07 (1.00, 1.14) 1184 (78.8)  1.02 (0.97, 1.07) 1.05 (1.01, 1.09) 
Homeless at any time in P12M  <.0001    <.0001   
  No 2134 (65.7)  1.57 (1.30, 1.88) 1.26 (1.09, 1.46) 2134 (80.9)  1.31 (1.14, 1.50) 1.15 (1.03, 1.29) 
  Yes  228 (42.0)  Reference Reference  228 (61.9)  Reference Reference 
Education attainment  0.04    <.0001   
  <High School  548 (60.3)  Reference Not  548 (73.8)  Reference Not 
  High School diploma or equivalent  667 (60.8)  1.01 (0.90, 1.13) significant  667 (75.1)  1.02 (0.94, 1.10) significant 
  >High School 1147 (66.5)  1.10 (1.02, 1.19)  1147 (83.7)  1.13 (1.06, 1.21)  
Poverty level during P12M  <.0001    <.0001   
  Above poverty level 1281 (68.3)  1.19 (1.11, 1.28) Not 1281 (84.1)  1.15 (1.10, 1.21) 1.06 (1.01, 1.12) 
  At or below poverty level 1013 (57.3)  Reference significant 1013 (72.8)  Reference Reference 
Behavior (Self-reported)         
Injection drug use during P12M  0.64    0.40   
  No 2308 (63.6)  1.06 (0.82, 1.38) Not 2308 (79.3)  1.10 (0.88, 1.36) Not 
  Yes 45 (59.8)  Reference significant 45 (72.2)  Reference significant 
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Characteristic 
Durable viral suppression Most recent viral suppression 
Sample size 
n (% Durable 
VL 
suppressed) 
Chi-
square
%
 
p-value 
Unadjusted PR Adjusted PR Sample size 
n (% Recent 
VL 
suppressed) 
Chi-
square 
p-
value
%
 
Unadjusted PR Adjusted PR 
Non-injection drug use during P12M  0.005    0.03   
  No 1716 (65.5)  1.13 (1.04, 1.23) Not 1716 (80.4)  1.06 (1.00, 1.13) Not 
  Yes 637 (58.0)  Reference significant 637 (75.5)  Reference significant 
Binge drinking in P12M  0.05    0.007   
  No 1922 (64.5)  1.10 (1.00, 1.22) Not 1922 (80.2)  1.09 (1.02, 1.15) Not 
  Yes 417 (58.6)  Reference significant 417 (73.9)  Reference significant 
Depression in P12M  <.0001    0.0005   
  No depression 1779 (66.3)  Reference Reference 1779 (81.3)  Reference Not 
  Other depression 295 (58.4)  0.88 (0.78, 1.00) 0.95 (0.85, 1.07) 295 (73.3)  0.90 (0.84, 0.97) significant 
  Major depression 258 (50.1)  0.76 (0.65, 0.87) 0.83 (0.73, 0.94) 258 (70.9)  0.87 (0.79, 0.96)  
Overall adherence  <.0001    <.0001   
  Not adherent 224 (49.3)  Reference Reference 224 (62.0)  Reference Reference 
  Partial adherent 744 (62.0)  1.26 (1.03, 1.53) 1.13 (0.97, 1.33) 744 (80.7)  1.30 (1.12, 1.51) 1.19 (1.09, 1.30) 
  100% adherent 1311 (70.0)  1.42 (1.17, 1.72) 1.23 (1.06, 1.44) 1311 (84.8)  1.37 (1.18, 1.58) 1.23 (1.12, 1.35) 
Clinical status and care (from MRA)         
Type of AIDS  0.42    0.01   
  No AIDs  699 (65.3)  1.04 (0.95, 1.14) Not  699 (83.0)  1.07 (1.01, 1.13) Not 
  AIDs  1661 (62.8)  Reference significant 1661 (77.5)  Reference significant 
Nadir CD4 count (cells/mm3)  <.0001    0.0004   
  0-199 1177 (61.6)  Reference Reference 1177 (76.1)  Reference Reference 
  200-349  653 (58.7)  0.95 (0.87, 1.05) 0.94 (0.86, 1.02)  653 (79.5)  1.05 (0.98, 1.12) 1.00 (0.94, 1.07) 
  350-499  278 (68.3)  1.11 (1.00, 1.23) 1.05 (0.95, 1.16)  278 (84.1)  1.11 (1.02, 1.20) 1.05 (0.97, 1.13) 
  500+  238 (81.5)  1.32 (1.19, 1.47) 1.29 (1.16, 1.43)  238 (89.2)  1.17 (1.08, 1.28) 1.11 (1.01, 1.22) 
Prescribed antiretroviral (ART) 
therapy in P12M  
<.0001   
 
<.0001   
1-1.EFV/TDF/FTC* (AI) 1064 (69.0)  Reference Reference 1064 (84.1)  Reference Reference 
1-2.ATV/r + TDF/FTC* (AI)  520 (55.5)  0.80 (0.71, 0.91) 0.84 (0.76, 0.94)  520 (74.8)  0.89 (0.83, 0.96) 0.93 (0.87, 1.00) 
2-5.LPV/r + ABC/3TC* or 
TDF/FTC* (BI) 
 325 (61.1)  0.89 (0.81, 0.97) 0.88 (0.81, 0.96)  325 (73.5)  0.87 (0.81, 0.94) 0.88 (0.82, 0.95) 
3-2.NVP + (ABC/3TC* or 
TDF/FTCa or ZDV/3TC*) 
 154 (79.1)  1.15 (0.99, 1.32) 0.99 (0.83, 1.19)  154 (90.4)  1.08 (0.99, 1.16) 1.03 (0.94, 1.14) 
1-3.DRV/r + TDF/FTC* (AI)  150 (46.5)  0.67 (0.53, 0.85) 0.69 (0.55, 0.86)  150 (69.5)  0.83 (0.73, 0.93) 0.88 (0.79, 0.99) 
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Characteristic 
Durable viral suppression Most recent viral suppression 
Sample size 
n (% Durable 
VL 
suppressed) 
Chi-
square
%
 
p-value 
Unadjusted PR Adjusted PR Sample size 
n (% Recent 
VL 
suppressed) 
Chi-
square 
p-
value
%
 
Unadjusted PR Adjusted PR 
3-3.(ATV or ATV/r or DRV/r or 
FPV/r or LPV/r or SQV/r) + 
ZDV/3TC* 
 148 (56.9)  0.82 (0.70, 0.97) 0.89 (0.77, 1.03)  148 (67.6)  0.80 (0.70, 0.93) 0.87 (0.77, 0.99) 
*
 3TC may substitute for FTC or vice versa.   
PRs that were significantly larger than 1 are colored in red while those significantly less than 1 are in blue. 
%
Rao-Scott modified chi-square test 
Table 3.13 Logistic regression models of factors associated with dose-adherence and side effect receiving top six popular ART 
regimen—Medical Monitoring Project, 2009 
Characteristic 
100% Dose adherence Troubled by side effects 
Sample size 
n (% Dose 
adherence 
100%) 
Chi-
square
%
  
p-value 
Unadjusted PR Adjusted PR Sample size 
n (% Had 
side effect) 
Chi-
square
%
  
p-value 
Unadjusted PR Adjusted PR 
Total patients 2279 (84.4)    2259 (16.2)    
Demographic (Self-reported)         
Gender   0.02    0.14   
  Male 1676 (85.9)  Reference Reference 1662 (16.1)  Reference  
  Female  572 (80.5)  0.94 (0.89, 0.98) 0.92 (0.88, 0.97)  566 (17.4)  1.08 (0.84, 1.39) Not 
  Transgender or intersex 32 (81.7)  0.95 (0.80, 1.13) 0.96 (0.81, 1.14) 32 ( 4.7)  0.30 (0.08, 1.11) significant 
Age at interview      0.06    0.25   
  18-29 yrs  166 (78.4)  Reference Reference  164 (18.8)  Reference  
  30-39 yrs  403 (82.2)  1.05 (0.95, 1.15) 1.05 (0.96, 1.15)  397 (19.2)  1.02 (0.67, 1.57)  
  40-49 yrs  912 (85.1)  1.09 (0.99, 1.19) 1.09 (1.00, 1.18)  906 (16.0)  0.86 (0.58, 1.27) Not 
  >=50 yrs  799 (86.0)  1.10 (1.00, 1.20) 1.08 (0.99, 1.17)  793 (14.4)  0.77 (0.51, 1.15) significant 
Race/Ethnicity  0.08    0.04   
  Hispanic  473 (86.5)  Reference   471 (14.2)  Reference Reference 
  Non-Hispanic Black  945 (81.6)  0.94 (0.90, 0.99)   935 (13.9)  0.98 (0.77, 1.24) 0.93 (0.72, 1.19) 
  Non-Hispanic White  762 (87.1)  1.01 (0.95, 1.07) Not  757 (19.3)  1.36 (1.05, 1.75) 1.36 (1.06, 1.74) 
  Other  100 (81.0)  0.94 (0.82, 1.07) significant 97 (23.1)  1.62 (0.96, 2.75) 1.44 (0.87, 2.39) 
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Characteristic 
100% Dose adherence Troubled by side effects 
Sample size 
n (% Dose 
adherence 
100%) 
Chi-
square
%
  
p-value 
Unadjusted PR Adjusted PR Sample size 
n (% Had 
side effect) 
Chi-
square
%
  
p-value 
Unadjusted PR Adjusted PR 
Foreign born (Country of birth other 
than US or Puerto Rico)  
0.78   
 
0.22   
  No, not born in foreign country  1975 (84.4)  Reference Not 1958 (16.7)  Reference Not 
  Yes, born in foreign country   305 (85.0)  1.01 (0.95, 1.06) considered  302 (13.5)  0.81 (0.56, 1.16) significant 
Length of time since HIV diagnosis  0.44    0.80   
  <5 years  569 (86.3)  Reference   564 (16.8)  Reference  
  5-9 years  563 (84.1)  1.03 (0.99, 1.08) Not  559 (15.1)  1.02 (0.78, 1.32) Not 
  >=10 years 1147 (83.6)  1.01 (0.95, 1.07) considered  1136 (16.5)  0.92 (0.66, 1.27) considered 
Homeless at any time in P12M  0.36    0.07   
  No 2070 (84.7)  1.04 (0.95, 1.14) Not 2053 (15.7)  0.73 (0.53, 0.98) Not 
  Yes  210 (81.4)  Reference significant  207 (21.7)  Reference significant 
Education attainment  0.09    0.26   
  <High School  521 (80.9)  Reference   513 (16.3)  Reference  
  High School diploma or equivalent  647 (86.1)  1.06 (1.01, 1.13) Not  644 (14.1)  0.87 (0.63, 1.19) Not 
  >High School 1112 (85.1)  1.05 (1.00, 1.11) significant 1103 (17.3)  1.06 (0.84, 1.35) considered 
Poverty level during P12M  0.005    0.07   
  Above poverty level 1252 (86.6)  1.07 (1.02, 1.12) Not 1244 (14.6)  0.80 (0.63, 1.02) 0.80 (0.64, 1.00) 
  At or below poverty level  965 (81.2)  Reference significant  953 (18.2)  Reference Reference 
Behavior (Self-reported)         
Injection drug use during P12M  0.14    0.78   
  No 2232 (84.9)  1.33 (0.91, 1.96) Not 2216 (16.3)  1.09 (0.59, 2.02) Not 
  Yes 39 (63.7)  Reference significant 37 (15.0)  Reference considered 
Non-injection drug use during P12M  <.0001    0.31   
  No 1664 (87.4)  1.14 (1.08, 1.20) 1.11 (1.06, 1.17) 1652 (15.8)  0.89 (0.72, 1.11) Not 
  Yes 608 (76.7)  Reference Reference 602 (17.7)  Reference considered 
Binge drinking in P12M  <.0001    0.61   
  No 1857 (86.6)  1.15 (1.09, 1.21) 1.12 (1.06, 1.17) 1842 (16.4)  1.07 (0.81, 1.43) Not 
  Yes 400 (75.1)  Reference Reference 398 (15.3)  Reference considered 
Depression in P12M  0.001    >.0001   
  No depression 1735 (86.3)  Reference Reference 1727 (12.3)  Reference Reference 
  Other depression 278 (81.7)  0.95 (0.89, 1.00) 0.95 (0.90, 1.00) 273 (21.2)  1.73 (1.33, 2.25) 1.68 (1.26, 2.25) 
  Major depression 238 (76.1)  0.88 (0.81, 0.96) 0.91 (0.85, 0.99) 235 (37.2)  3.03 (2.20, 4.16) 3.00 (2.12, 4.25) 
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Characteristic 
100% Dose adherence Troubled by side effects 
Sample size 
n (% Dose 
adherence 
100%) 
Chi-
square
%
  
p-value 
Unadjusted PR Adjusted PR Sample size 
n (% Had 
side effect) 
Chi-
square
%
  
p-value 
Unadjusted PR Adjusted PR 
Overall adherence      <.0001   
  Not adherent     217 (22.2)  Reference Reference 
  Partial adherent     739 (20.2)  0.91 (0.67, 1.23) 1.09 (0.81, 1.47) 
  100% adherent     1303 (13.1)  0.59 (0.44, 0.78) 0.76 (0.56, 1.03) 
Clinical status and care (from MRA)         
Type of AIDS  0.61    0.75   
  No AIDS  670 (85.3)  1.01 (0.96, 1.07) Not  663 (15.8)  Not Not 
  AIDs  1608 (84.1)  Reference considered 1595 (16.4)  considered considered 
Nadir CD4 count (cells/mm3)  0.05    0.52   
  0-199 1140 (82.3)  Reference  1130 (15.9)    
  200-349  629 (85.9)  1.04 (0.98, 1.11) Not  623 (16.9)  Not Not 
  350-499  268 (89.8)  1.09 (1.02, 1.17) significant  267 (13.8)  considered considered 
  500+  227 (86.5)  1.05 (0.98, 1.13)   224 (18.4)    
Prescribed antiretroviral (ART) therapy 
in P12M  
0.002   
 
0.09   
1-1.EFV/TDF/FTC* (AI) 1040 (87.6)  Reference Reference 1030 (15.3)  Reference Reference 
1-2.ATV/r + TDF/FTC* (AI) 497 (83.2)  0.95 (0.89, 1.01) 0.96 (0.90, 1.02) 492 (14.6)  0.95 (0.74, 1.22) 0.89 (0.69, 1.15) 
2-5.LPV/r + ABC/3TC* or TDF/FTC* 
(BI) 
313 (78.0)  0.89 (0.82, 0.97) 0.90 (0.83, 0.97) 312 (18.5)  1.21 (0.87, 1.69) 1.17 (0.86, 1.59) 
3-2.NVP + (ABC/3TC* or TDF/FTCa 
or ZDV/3TC*) 
151 (87.6)  1.00 (0.93, 1.08) 0.98 (0.91, 1.05) 150 (15.1)  0.99 (0.53, 1.84) 1.19 (0.66, 2.13) 
1-3.DRV/r + TDF/FTC* (AI) 140 (81.3)  0.93 (0.85, 1.01) 0.91 (0.83, 0.99) 139 (26.6)  1.73 (1.21, 2.49) 1.65 (1.16, 2.36) 
3-3.(ATV or ATV/r or DRV/r or 
FPV/r or LPV/r or SQV/r) + 
ZDV/3TC* 
138 (78.7)  0.90 (0.84, 0.96) 0.91 (0.84, 0.98) 139 (26.6)  0.90 (0.57, 1.42) 0.89 (0.57, 1.39) 
*
 3TC may substitute for FTC or vice versa.   
PRs that were significantly larger than 1 are colored in red while those significantly less than 1 are in blue. 
%
Rao-Scott modified chi-square test 
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CHAPTER 4 DISCUSSION 
Although many clinical trials and cohort studies have been conducted to compare the 
efficacy and effectiveness of different ART regimens, this is the first analysis that provides a 
nationally representative profile of current ART usage and related health outcomes, including 
viral suppression, adherence and side effects, of HIV-infected adults in care in the United States. 
MMP is a national surveillance system that uses probability sampling methods. Both interviews 
and medical record abstractions were collected from 23 project areas (16 states, 1 U.S. territory, 
and 6 health jurisdictions) in the United States. Large proportion of MMP participants were male 
(71%) and with age of over 40 (65%). Seventy-seven percent of HIV infected adults in care had 
been diagnosed for more than 4 years. ART, especially HAART, is the key contributor in 
extending and improving these patients’ lives. The prescription of ART was high among MMP 
participants (88.6%). Prescribed regimens were further categorized into five major groups based 
on most recent DHHS HIV treatment guidelines [32]: preferred-regimens, alternative-regimens, 
maybe-selected-regimens, not-recommended-regimens and other-regimens (Table 2.2). 
Approximately half of the participants on ART took preferred-regimens. Multivariate analysis 
suggested that the patients not prescribed preferred-regimens were more likely to be older (>50 
years old), with diagnosed with HIV >5 years, at/below poverty level, and insured by Medicare 
or both Medicare and Medicaid insurances. The disconnection between preferred-regimens and 
long-term patients can be explained by the fact that patients diagnosed a long time age would 
continue to use effective regimens from prescribed at a time when more limited ART options 
were available, while the  regimen classification system applied here was based on most recent 
DHHS Art treatment guidelines for ART initiation in naïve patients [32]. 
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The top six popular regimens were (1-1) EFV/TDF/FTC, (1-2) ATVr with TDF/FTC, (2-5) 
LPVr with ABC/3TC or TDF/FTC, (3-2) NVP with (ABC/3TC or TDF/FTC or ZDV/3TC), (1-
3) DRVr with TDF/FTC, and (3-3) any PI (ATV or ATVr or DRVr or FPVr or LPVr or SQVr) 
with ZDV/3TC. Each was prescribed to 29.3%, 13.4%, 8.8%, 4.0%, 4.0%, and 3.8% of the MMP 
participants, respectively. All of them were “cocktail” regimens based on NRTI backbone with 
addition of NNRTI or PI. (1-1)EFV/TDF/FTC, the most popular and most recommended ART 
regimen, is simple to use (available in a fixed-dose pill, one pill once daily) and was proved to be 
the most efficient and safe regimen in a 9-Country 3-Way random clinical trial [60]. Different 
NRTI backbone were employed in these six regimens: TDF/FTC for regimens (1-1), (1-2), and 
(1-3); ZDV/3TC for regimen (3-3); either one or ABC/3TC for (2-5) and (3-2). However, 
experts’ panel review had suggested that these recommended regimens (TDF-based or ZDV-
based) are comparable in terms of efficacy and safety [61]. On the other hand, regimens 
containing NVP are more cost-effective than with EFV [61].  
There was a high concordance between ART prescription and self-reported ART use. Among 
MMP participants, 86.2% were prescribed ART and were currently taking ART, while 8.9% 
participants were not currently taking ART, neither were they prescribed. Only 2.9% patients 
were prescribed but not taking ART and 2.0% who were currently on ART but were not 
prescribed ART within the 2009 surveillance period. This finding is consistent with other reports 
of relatively high correspondence between self-report and medical record abstraction [62, 63]. 
ART was crucial for viral suppression. Among MMP participants, only 11% were not 
prescribed ART. However, significantly lower proportion achieved viral suppression in non-
ART users than in ART users. Therefore, as recommended in recent treatment guidelines [32], 
ART should be recommended to every HIV-infected patient to maintain suppressed viral load 
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and health status. Out-of-care HIV patients are at high risk because they do not have access to 
ART. 
Understanding the relative impact of different regimens may inform efforts and resources to 
increase appropriate ART medication among HIV-infected patients. Different regimens were 
compared by means of viral suppression, drug adherence and side effects using multivariate 
logistic regression. The major ART groups (preferred-regimens, alternative-regimens, maybe-
selected-regimens) performed similarly. Minor differences were observed for not-recommended-
regimens and other-regimens. Patients on other-regimens (regimens not on the DHHS 
recommended list) were less likely to achieve viral suppression, or to be dose adherent. Besides, 
patients on not-recommended-regimens were more likely to have side effects. Comparison of top 
six regimens revealed small disparities in adjusted prevalence ratios for four outcome variables. 
Regimen (1-3) was the worst among six top popular regimens. Patients on regimens (1-2), (2-5) 
and (1-3) were less likely to achieve viral suppression in durable VL and most recent VL while 
those on (1-3) and (3-3) were less likely to fully adherent to medications. In addition, patients on 
regimen (1-3) were more prone to side effects compared to regimen (1-1).  
The differences in impacts of individual regimen or major regimen groups on the health 
outcomes were subtle. The adjusted prevalence ratios of regimens for viral suppression, ART 
adherence, and trouble with side effects were fairly close to 1, although statistically significantly 
different from 1. Comparable health outcomes from different ART regimens were also reported 
by Martin and colleagues using a cohort study [64]. Such findings are in concordant with WHO 
(World Health Organization) experts’ panel review comments [61].  
Other factors associated with viral suppression were age, race, length of HIV diagnosis, 
homeless status, depression, drug adherence, and nadir CD4 counts. Patients that were older, 
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diagnosed with HIV less recently, not homeless, not depressed, highly drug adherent, with high 
CD4 counts were more likely to achieve viral suppression. Non-Hispanic black patients were less 
likely to be viral suppressed compared to Hispanic race, while non-Hispanic white were more 
likely to be suppressed. Similar conclusions have been reported by several other studies [35, 65-
68].  
Other factors associated with dose-adherence included age, homeless status, poverty level, 
certain behaviors (such as binge drink, non-injection drug usage), and depression level. 
Consistent with the published results [35, 68-70], younger, homeless, low poverty level, binge 
drinker and non-injection drug users were less likely to be adherent to ART medications.  
Logistic regression model suggested that self-reported side effects were independently 
correlated with race, poverty level and depression, as well as ART regimen. Non-Hispanic white 
patients were more likely to develop side effects. Participants above poverty level and not 
depressed were less likely to have side effects. There was a statistically significant positive 
association between depression and side effects. Logistic regression modeling results indicated 
that the aPRs of side effects almost doubled for those reporting with other depression (PR 1.8, CI 
1.5-2.2 for model of major regimen groups; PR 1.7, CI 1.3-2.3 for model of six top regimens), 
and tripled for those reporting with major depression (PR 2.9, CI 2.3-3.7 for model of major 
regimen groups; PR 3.0, CI 2.1-4.3 for model of six top regimens). The impact of depression on 
side effects could be complicated. Several studies had suggested that depression were associated 
with non-adherence [35, 71, 72], while the latter could induce drug resistance and side effects 
[69]. On the other hand, drug interactions between anti-depressants and ART medications may 
also contribute to the development of side effects. Currently a full list of medications for 
depression in not covered by medical record abstraction in MMP, thus this effect could hardly be 
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evaluated. Nevertheless, this strong association between depression and side effects emphasizes 
the need and importance of active screening and treating for depression among HIV-infected 
patients [61].  
Although this thesis has focused on ART prescription/non-prescription, and regimen 
comparisons within those participants who were prescribed and took ART, it would be 
instructive to explore the discrepancies between doctors’ prescription and patients’ medication, 
and the consequences on viral suppression. MMP participants were categorized into four groups 
based on ART usage, as shown in Table 4.1, “Prescribed and Took”, “Prescribed and NOT 
took”, “NOT prescribed and Took”, and “NOT prescribed and NOT took”. The crude 
comparison suggested that two groups of “NOT Took” had significantly lower proportions of 
viral suppression. The percentage with recent/durable viral suppression were only 18.2%/11.4% 
and 15.4%/13.1% for “Prescribed and NOT Took” and “NOT prescribed and NOT took” groups, 
respectively. The survey questions on drug adherence and side effects were skipped for these two 
groups of participants. Significantly low proportion (23.2%) of patients were diagnosed with 
AIDS in the “NOT prescribed and NOT Took” group, compared to the other three groups 
(around 70%). This might be a reason why this group of patients was not exposed to ART. On 
the other hand, more than half of the participants in the “NOT prescribed and Took” group had 
suppressed viral load (59.7% and 46.2% for recent and durable viral suppression, respectively); 
although such proportions were less than those of “Prescribed and Took” group (79.9% and 
64.4% for recent and durable viral suppression, respectively). Besides, higher percentage 
(26.1%) of participants in “NOT prescribed and Took” group was troubled with side effects than 
that (17.1%) of “Prescribed and Took” group. These findings reinforce the importance of ART 
and furthermore, the significance of adherence [35, 65-68]. The solid lifelong commitment to 
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ART is the key in fighting HIV/AIDS [32]. Additionally, routinely follow-up care after ART 
initiation is necessary to maintain viral suppression and minimize side effects. Unfortunately, 
multivariate regression analyses for the three minor groups were not appropriate at this point 
because of the relatively small sample sizes. In the future, such modeling may become possible if 
multiple years of MMP data can be combined. Further research to characterize and target these 
three minor groups will help to optimize the use of ART regimens and maximize their benefits 
for all HIV-infected patient population.  
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Table 4.1 Crude comparison of prescription vs. medication by outcomes of interest—Medical Monitoring Project, 2009 
ART 
Prescription vs. Medication 
AIDS 
diagnosis 
Most recent 
VL 
suppressed 
Durable VL 
suppressed 
100% Adherence Had side 
effect in past 
30 days Dose Instruction Schedule 
n=4193 n=2904 n=3013 n=2434 n=3067 n=1684 n=2617 n=639 
 n Col% n Row% n Row% n Row% n Row% n Row% n Row% n Row% 
Prescribed and Took  3605 86.2 2640 72.0 2877 79.9 2327 64.4 2994 85.6 1642 68.9 2553 71.7 617 17.1 
Prescribed and NOT Took  128 2.9 86 68.7 25 18.2 16 11.4 -- -- -- -- -- -- -- -- 
NOT prescribed and Took  91 2.0 64 71.3 55 59.7 44 46.2 73 86.2 42 72.2 64 70.5 22 26.1 
NOT prescribed and NOT took 369 8.9 91 23.2 56 15.4 47 13.1 -- -- -- -- -- -- -- -- 
p-value*  <.0001 <.0001 <.0001 0.90 0.59 0.82 0.07 
*Rao-Scott modified chi-square test 
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CHAPTER 5 STUDY LIMITATIONS 
Despite the advantages of providing nationally representative estimates, this study is subject 
to several limitations:  
1
st
, MMP study is limited to HIV-infected adults receiving care therefore it cannot be 
generalized to all HIV-infected persons in the United States.  
2
nd
, the overall response rate was relatively low (42.4%). Although non response weighting 
was used, non-response bias can affect the reliability of population estimates. 
3
rd
, MMP is a cross-sectional study, the risk factors and outcomes were measured at the same 
time, thus finding of any significant association could not be proved as causal.  
4
th
, part of the data of this analysis were obtained from survey; while survey was collected 
via in-person interviews, certain responses might be subject to recall and social desirability bias, 
for example, the drug adherence may be over-reported. Moreover, data abstracted from medical 
records may involve recording errors.  
5
th
, it is difficult to determine the temporal sequence of outcomes and HIV regimens. The 
viral load, drug adherence, and drug side effect may result from the history of ART treatment 
and demand modifications in most recent prescription.  
Finally, our logistic regression models can consider only a limited number of factors because 
of the relative small sample size, although MMP collected many more behavior and clinical 
information. Therefore, interpretation of presence or absence of significant finding might be 
potential confounded by other factors that the study did not examine. For instance, ART 
prescription can potentially be affected by patient’s health condition and doctor’s preferences. 
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CHAPTER 6 CONCLUSIONS 
This thesis provides a nationally representative profile of current ART usage and related 
health outcomes, including viral suppression, adherence and side effects, of HIV-infected adults 
receiving care in the United States in 2009. Results showed that a large volume of HIV-infected 
adults receiving care was prescribed with ART (88.6%). Cocktail regimens based on two NRTIs 
with addition of NNRTI or PIs were most commonly employed. Approximately half of the 
participants prescribed ART took preferred-regimens and about 30% were using regimen (1-1) 
EFV/TDF/FTC. Of MMP participants who were prescribed ART, 96.5% self-reported took 
ART, 62.7% achieved suppression of durable VL, 77.8% achieved suppression of most recent 
VL, 83.5% were 100% dose-adherent, and 17.1% complained about side effects. Figure 6.1 
presented an overall picture of HIV-infected patients in the United States in 2009. Furthermore, 
the analyses results suggested that different regimens or regimen groups did not pose large 
differences in prevalence of viral suppression, adherence and side effects. However, use of ART 
is a key component in achieving and maintaining suppressed viral load. Therefore, as 
recommended by the recent treatment guidelines [32], ART should be prescribed to every HIV-
infected person regardless of CD4 count or clinical symptoms. Overall, MMP provided 
comprehensive information about the behaviors, medical care, and health status of the patient 
samples selected to represent HIV-infected adults receiving medical care in the United States. 
Results presented in this study could be useful for future strategic planning of HIV care. 
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Figure 6.1 Number and percentage of HIV-infected persons engaged in selected stages of the 
continuum of HIV care—United States, 2009 
0
40
80
120
HIV infected* HIV 
diagnosed*
Linked to HIV 
care$
Retained in 
HIV care%
Prescribed 
ART#
Taking ART& Recent VL 
suppressed**
Durable VL 
suppressed**
AIDS
NO 
AIDS
Others
NOT-recommended regimens
Maybe-selected regimens
Alternative regimens
Preferred regimens
425,020
1,148,200
330,665
410,144
479,706
724,262
940,600
257,160
* Numbers of HIV-infected, HIV-diagnosed, AIDs-diagnosed patients were obtained from [11]. 
$
 Calculated as estimated number of diagnosed × estimated percentage linked to care (77%) [72-74].   
%
 Calculated as estimated number of diagnosed × estimated percentage retained in care (51%) [72-74].  
# Calculated as estimated number of retained in HIV care × percentage prescribed ART in MMP (88.6%). 
&
 Calculated as estimated number of prescribed with ART × percentage took ART in MMP (96.5%). 
** Calculated as estimated number of prescribed with ART × percentage of viral suppression in MMP (62.7% for 
durable VL and 77.8% for most recent VL). 
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